

the Ophthalmologist™

In My View

How to separate the pioneers from the buccaneers

18

NextGen

A non-invasive approach to refractive correction

38 – 40

Profession

How the Himalayan Cataract Project keeps on climbing

44 – 48

Sitting Down With

Elizabeth Yeu, aspiring for greatness

50 – 51

A Life-Changing Gift

One patient and one physician on what it really means to restore 20/20 vision.

20 – 27



JUST GO

The CATALYS® System

TAKE THE
FAST TRACK
TO SURGICAL
EXCELLENCE

MAKE YOUR MOVE
AT ESCRS BOOTH
#B500 HALL B



CATALYS®
Precision Laser System


INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR THE CATALYS® PRECISION LASER SYSTEM

INDICATIONS: The CATALYS® Precision Laser System is indicated for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, phacofragmentation, and the creation of single-plane and multi-plane arc cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure. **WARNINGS:** Prior to INTEGRAL GUIDANCE System imaging and laser treatment, the suction ring must be completely filled with sterile buffered saline solution.

This promotional piece is addressed only to members of the medical class. For a complete listing of indications, contraindications, precautions, warnings and adverse events, please refer to the CATALYS® System operator manual.



Image of the Month




Fun After Hours

These images were submitted by Trina Toyama, a Clinical Applications Specialist at Heidelberg Engineering. “As a technician, I have had the privilege of using many precision eyecare instruments and cameras. Though the retina is an endless source of fascination, over my career I have used non-ocular images as a way to better understand the functions, strengths, and limitations of a device. Turning the camera to the plants and debris surrounding clinic buildings created these images, which were acquired with a SPECTRALIS diagnostic imaging platform.” Using only the tools and features available with the system – such as automated real-time tracking – Toyama says that the device “easily transitions from the most demanding science to playfully act as a fascinating high magnification camera with a lot of latitude for after-hours fun.” But can you guess what they are?

Credit: Trina Toyama, Clinical Applications Specialist, Heidelberg Engineering. *Top left, flower; top right, leaf; bottom left, acorn caps; bottom right, flower.*

Do you have an image you'd like to see featured in *The Ophthalmologist*?
Contact edit@theophthalmologist.com



10



20



In My View

- 16 Think LASIK has reached its peak? Think again. **Rod Solar** says the refractive market could be multiplied in less than a decade, but only the most adaptable will enjoy the benefits.
- 18 In this digital age, are we doing enough to champion truly great minds? That's the question **Karl Stonecipher** asks in his time-bending piece, "Pioneer or Buccaneer?"

03 Image of the Month

- 07 **Editorial**
The Gift of Sight...,
by Ruth Steer.

Upfront

- 10 Blinded by the Light
- 11 Inject or Reject
- 12 Not Immune to Damage
- 14 Changing the Program
- 14 Bitesize Breakthroughs

On The Cover




Artwork inspired by the uplifting story of Crystal Ellis, a corneal transplant recipient and Transplant Games of America medal winner.

Feature

- 20 **A Life-Changing Gift**
Corneal transplants are all in a day's work for an ophthalmologist – but for a patient like Crystal Ellis, they mean the world. With the help of her physician, Christine Sindt, she explains what it's really like to suffer sight loss – and how it feels to get it back.

iStent
inject®



TRANSFORMING MIGS IN MORE WAYS THAN ONE.

Optimized Outflow: Two multi-directional stents designed to restore natural outflow

Clinically Proven: Significant IOP reduction across a wide range of clinical studies^{1,2}

Procedural Elegance: Predictability and precision to meet the needs of your practice

Proven Safety: Safety profile similar to cataract surgery alone¹



ESCRS BOOTH B330

All with the exceptional customer support you've come to expect from Glaukos.

www.glaukos.com | + 1.949.367.9600

The iStent *inject*® is intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma. The iStent *inject*® can deliver two (2) stents on a single pass, through a single incision. The implant is designed to stent open a passage through the trabecular meshwork to allow for an increase in the facility of outflow and a subsequent reduction in intraocular pressure. The device is safe and effective when implanted in combination with cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and conventional glaucoma surgery.

REFERENCES: 1. iStent *inject*® Trabecular Micro-Bypass System: Directions for Use, Part #45-0176. 2. Hengerer FH. Personal experience with second-generation trabecular micro-bypass stents in combination with cataract surgery in patients with glaucoma: 3-year follow-up. ASCRS 2018 Presentation.

© 2018 Glaukos Corporation. Glaukos and iStent *inject* are registered trademarks of Glaukos Corporation. PM-EU-0031

GLAUKOS®
Transforming Glaucoma Therapy

BEAT YOUR PERSONAL BEST. FAST. EFFICIENT. POWERFUL.



Jan Frodeno
Triathlon Olympic Champion
Double IRONMAN World Champion


ANTERION®

Experience the power of swept-source OCT technology at its best. Perform the most relevant anterior segment exams in one modular, upgradeable platform.

Introducing ANTERION.

Take the lead with a dynamic, workflow-efficient imaging platform that delivers powerful results.

Reserve yours at ESCRS Stand B608.



200386-001_INT_AE18 © Heidelberg Engineering GmbH



CORNEA



CATARACT



METRICS

www.anterion.com

**HEIDELBERG
ENGINEERING**

Editor - Ruth Steer
ruth.steer@texerepublishing.com
Assistant Editor - Phoebe Harkin
phoebe.harkin@texerepublishing.com
Content Director - Rich Whitworth
rich.whitworth@texerepublishing.com
Publishing Director - Neil Hanley
neil.hanley@texerepublishing.com
Associate Publisher - Abigail Mackrill
abigail.mackrill@texerepublishing.com

Head of Design - Marc Bird
marc.bird@texerepublishing.com
Designer - Hannah Ennis
hannah.ennis@texerepublishing.com
Junior Designer - Charlotte Brittain
charlotte.brittain@texerepublishing.com

Digital Team Lead - David Roberts
david.roberts@texerepublishing.com
Digital Producer Web/Email - Peter Bartley
peter.bartley@texerepublishing.com
Digital Producer Web/App - Abygail Bradley
abygail.bradley@texerepublishing.com
Audience Insight Manager - Tracey Nicholls
tracey.nicholls@texerepublishing.com
Traffic & Audience Database Coordinator - Hayley Atiz
hayley.atiz@texerepublishing.com

Traffic & Audience Associate - Lindsey Vickers
lindsey.vickers@texerepublishing.com
Traffic Manager - Jody Fryett
jody.fryett@texerepublishing.com
Traffic Assistant - Dan Marr
dan.marr@texerepublishing.com

Events Manager - Alice Daniels-Wright
alice.danielswright@texerepublishing.com
Marketing Manager - Katy Pearson
katy.pearson@texerepublishing.com
Financial Controller - Phil Dale
phil.dale@texerepublishing.com
Accounts Assistant - Kerri Benson
kerri.benson@texerepublishing.com

Vice President (North America) - Fedra Pavlou
fedra.pavlou@texerepublishing.com
Chief Executive Officer - Andy Davies
andy.davies@texerepublishing.com
Chief Operating Officer - Tracey Peers
tracey.peers@texerepublishing.com

Change of address
info@texerepublishing.com
Hayley Atiz, The Ophthalmologist,
Texere Publishing, Haig House, Haig
Road, Knutsford, Cheshire, WA16 8DX, UK

General enquiries
www.texerepublishing.com
info@texerepublishing.com
+44 (0) 1565 745 200
sales@texerepublishing.com

Distribution
The Ophthalmologist (ISSN 2051-4093),
is published monthly by Texere Publishing,
Haig House, Haig Road, Knutsford,
Cheshire WA16 8DX, UK
Single copy sales £15 (plus postage, cost available
on request info@texerepublishing.com)
Non-qualified annual subscription cost is
£110 plus postage

Reprints & Permissions - tracey.nicholls@texerepublishing.com
The opinions presented within this publication are those of the authors
and do not reflect the opinions of The Ophthalmologist or its publishers,
Texere Publishing. Authors are required to disclose any relevant financial
arrangements, which are presented at the end of each article, where relevant.
© 2018 Texere Publishing Limited. All rights reserved.
Reproduction in whole or in parts is prohibited.



Credit: Ate Kwaale, Mekelle, Ethiopia.

44

In Practice

- 30 **DME, Steroids and Glaucoma**
Intravitreal steroids for DME:
Charles Wykoff discusses
which patients can benefit, and
addresses concerns associated
with the therapy.
- 33 **The Matchmaker**
Paul Ursell introduces his
cataract training program –
an easy-to-use system that
offers patients lower risks of
complications, regardless of
surgeon experience.

NextGen

- 38 **Engineering Non-Invasive
Refractive Correction**
Mechanical engineer,
Sinisa Vukelic, shares the
science behind femtosecond
laser-induced corneal
crosslinking, and explains why
the procedure could change
refractive surgery forever.

Profession

- 44 **Climbing Mountains for a Cure**
From Bhutan to West Bengal,
Tibet to Tanzania, Geoff Tabin
explains the origins of The
Himalayan Cataract Project
and looks back on an almost
30-year journey.

Sitting Down With...

- 50 Elizabeth Yeu, Cataract and
Refractive Surgeon at Virginia
Eye Consultants, VA, USA

This is Sophi.

The beginning of a new era
in Phaco Surgery.

Sophi, the first battery driven phaco system, operates fully without any annoying connection cables and is equipped with an integrated air compressor.

The centerpiece of Sophi is its «Triple Pump Fluidics». This fluidic system is designed for better control of anterior chamber stability during the entire surgery. Sophi's pioneering and smart design of consumables leads to high functionality and economic benefits.

Mobility – Simplicity - Safety



Date: 22. 09. 2018
Time: 15.00
Location: Booth C106, ESCRS Vienna
See you in Vienna!



The Gift of Sight...

... is one that truly keeps giving. How and where the gift is presented can vary widely, but the impact is always great.

Editorial



If I were to ask you what you find most rewarding about your occupation (which I do on a regular basis), many of you will answer, “saving and improving sight” – unsurprising, as it is at the very core of what you do on a daily basis. But in a profession that encompasses many different specialties and disciplines – and varies across countries – how each individual ophthalmologist works to present this gift can be very different. And that’s why this issue features two inspiring – but quite different – approaches to saving sight.

In our cover feature, a patient and physician tell their stories. Crystal Ellis was in middle school when, for an unknown reason, she lost vision in one eye. She had a corneal transplant – but her vision did not improve. A positive individual, Crystal shares her experiences and perspectives as a patient. She also tells the heart-warming tale of her relationship with the cornea donor’s family, which really brings home the humanity integral to tissue and organ donation and how ‘precious’ that gift can be.

Around the same time, Crystal crossed paths with Christine Sindt – Professor of Ophthalmology at the University of Iowa hospital – whose innovative, custom-printed prosthetic lens technology went on to give Crystal 20/20 vision. Sindt explores her motivation to create a product to restore sight to those with corneal defects. And Crystal offers the perfect example of impact with her relentless motivation to ‘go for gold’ with her sight restored.

Following on the theme of the gift of sight, in our Profession section Geoff Tabin reveals the backstory to the Himalayan Cataract Project. Many of you will be familiar with the Project and its aims to eradicate global blindness. A truly inspiring individual, Tabin reveals how his interest in humanitarian efforts arose from him witnessing, first-hand, the global inequity in access to care. Almost 30 years after setting up the project, Tabin hasn’t wavered in his goal – and has extended the project well beyond the Himalayas to tackle blindness in many other countries.

The long and the short of it is: whether working for profit or for non-profit, the impact of the gift of sight is universal – and it is clear that everyone working in ophthalmology strives to make a real difference to people’s lives in their own way.

Ruth Steer
Editor

Upfront

Reporting on the innovations in medicine and surgery, the research policies and personalities that shape the practice of ophthalmology.

We welcome suggestions on anything that's impactful on ophthalmology; please email edit@theophthalmologist.com



Blinded by the Light

How blue light can induce retinal cell death

As a child, you may have been told, “Don’t spend so long in front of the TV... your eyes will go square!” – but what if the truth was more serious? A team at the University of Toledo, OH, USA, has found that blue light emitted by digital devices – and the sun – could permanently affect eyesight.

The research, led by Ajith Karunarathne, found that, when exposed to photoexcitation by blue light, the photoreceptor chromophore 11-cis retinal (11CR) and its photoproduct, all-

trans-retinal (ATR), could irreversibly distort PIP2 (a plasma membrane-bound phospholipid), disrupting downstream signaling and inducing oxidative damage, ultimately leading to cell death (Figure 1; 1)

“When retinal absorbs blue light, it becomes excited with photon energy. It releases that energy to oxygen, which generates highly oxidative chemical molecules, oxidizing important signaling lipids and proteins in cells, leading to cytotoxicity,” explains Karunarathne. And the results were the same when the team introduced retinal molecules to other non-receptor cell types. “Many reports have indicated the likelihood of blue light being cytotoxic,” says Karunarathne. “Our work clearly shows cell death occurs when retinal

molecules are present, even without photoreceptors.”

Given that photodegradation of this kind is linked with diseases such as AMD, can anything be done to avoid blue-light induced vision loss? “Avoiding prolonged exposure can help,” says Karunaratne, who also recommends sunglasses that not only block out UV light but also blue light, as well as advising against looking at cell phones or tablets in the dark.

Karunaratne has a worthy end goal in mind: “By learning more about the mechanisms of blindness, and searching for a method to intercept the toxic reactions caused by the combination of retinal and blue light, we hope to find a way to protect the vision of children growing up in a high-tech world (2).”

References

1. K Ratnayake et al., “Blue light excited retinal intercepts cellular signalling”, *Sci Rep*, 8, 10207 (2018). PMID: 29976989.
2. The University of Toledo, “UR chemists discover how blue light speeds blindness”, (2018). Available at: <https://tinyurl.com/y735e8cq>. Accessed August 16, 2018.




Figure 1. Proposed mechanism of how blue light-excited retinal induces PIP2 distortion.

Credit: K Ratnayake et al., (1).

Inject or Reject

Are vasoactive intestinal peptides the secret to corneal transplant survival?

Globally, there are millions of people with corneal blindness. But as countries struggle generally with donor cornea shortages, there is another factor that can affect the availability – and success – of corneal transplants: corneal endothelial cell integrity. If corneal endothelial cell density or function becomes inadequate after the transplant, graft opacity and/or rejection can occur, prompting research

into how to boost success rates.

Previous studies have revealed that vasoactive intestinal peptide (VIP) could enhance corneal cell survival during donor cornea storage, so a team from Massachusetts’ Eye and Ear Institute, Boston, USA, theorized that it could also help after corneal transplantation. “Our experiment revealed that our hypothesis was correct; the postoperative use of VIP improved the survival of corneal grafts in mice,” says Ahmad Kheirkhan, co-author of the paper (1).


The team is currently conducting further studies to unravel the exact mechanisms by which VIP enhances corneal graft survival, but Kheirkhan

points to one likely possibility: “VIP increases the migration of corneal endothelial cells, and decreases cell apoptosis by modulating resistance to pro-inflammatory cytokines.”

If the findings successfully translate to the clinic, the implications are significant, says Kheirkhan. “The use of VIP could help a large number of patients with corneal endothelial abnormalities, and enhance the outcome of corneal transplantation.”

Reference

1. V Satitpitakul et al., “Vasoactive intestinal peptide promotes corneal allograft survival”, *Am J Pathol*, [Epub ahead of print] (2018). PMID: 30097165.



Not Immune to Damage

Could activated T cells play a major role in driving neurodegeneration in glaucoma?

Glaucoma may be one of the leading causes of irreversible blindness worldwide but it is also one of the most mysterious. Elevated IOP might explain some of the pathology, but fails to explain glaucomatous damage occurring in patients with normal IOP – or in those whose IOP is maintained with therapy. As research teams the world over look to unravel the complex mechanisms driving the disease, a research group from Massachusetts's Eye and Ear Hospital, Boston, MA, USA, have evidence suggesting another factor might be at play: autoimmunity.

In brief, the team found that increased IOP could induce stress on

retinal neurons, leading to an elevated expression of heat shock proteins (HSPs), which, in turn, activates HSP-specific CD4+ T cells. Primed by commensal microbial flora, these T cells appear to induce progressive neurodegeneration. Dong Feng Chen, senior author on the paper (1), talks about their work.

The inspiration...

The work was started several years ago, when we first developed an inducible model of glaucoma in mice. We noted that a transient 2–3 week elevation of IOP resulted in progressive neuron loss even after the eye pressure returned to a normal range. This finding agreed with clinical observations that many glaucoma patients whose IOP was perfectly controlled would still undergo progressive vision loss. We began to speculate that elevated eye pressure triggered a long-lasting event, such as immune reactions, that contribute to vision loss. We thus looked for T and B cells in the glaucomatous retina and found T cells, which should not be


present because eye is thought to be an immune privileged site.

Unexpected findings...

We were surprised that mere elevation of eye pressure for a short time can induce T cell infiltration into the eye and cause T cell-mediated attack to neurons. Second, we were surprised that mice never exposed to bacteria are completely free from getting the disease, which truly indicates that elevation of eye pressure is not the direct cause of glaucoma, but rather the immune responses that lead to neuron and vision loss.

In humans...

By examining human blood samples, we showed that patients with primary open angle glaucoma (POAG) exhibited five-fold higher levels of HSP-specific T cells compared with control subjects, suggesting that a similar mechanism underlies the disease process in humans. Though only a 2–3 week elevation of IOP is sufficient to induce HSP-specific T cell responses in mice, we do not yet



know what duration in humans is required to induce a response. However, we speculate that at least some patients with normal tension glaucoma have had a transient elevation of IOP.

The impact...

We believe that our findings may lead to a future paradigm shift in both the diagnosis and management/treatment of glaucoma. First, though glaucoma causes permanent loss of vision, its early diagnosis has long been a challenge. Our finding may provide a potential biomarker for early diagnosis of the disease. Second, current therapies for glaucoma solely target reducing IOP, which slows vision loss rather than curing the disease. Our findings suggest new therapeutic targets, which may eventually lead to the cure of the disease.

Next steps...

Our goals are to develop and evaluate new interventions that target T cell or immune pathways for preventing vision loss in glaucoma. In collaboration with clinicians, we'd like to examine the possibility and potential of predicting disease development or progression by detecting abnormal or heightened T cell responses to HSPs.

Reference

1. H Chen et al., "Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma", *Nat Commun*, 9, 3209 (2018). PMID: 30097565.



Improve Your Surgical Efficiency

With Premium Quality
Single-Use Instruments

- Market leading portfolio
- Designed for excellent clinical performance



BVI Portfolio Features Malosa™ Single-Use Instruments

**For ordering information,
please call customer service**

US: 1-866-906-8080

EU: 44 (0) 1865 601256

bvimedical.com

Changing the Program


Reprogramming murine Müller glia to drive photoreceptor genesis and restoration of vision

Müller glia cells, abundant in the retina, are known to support retinal cell function. But they also have another support function: retinal regeneration. In cold-blooded vertebrates, such as zebrafish, it is well known that Müller glia can act as a source of stem cells to induce retinal repair and regeneration. But this regenerative capacity is absent in mammals; although cell proliferation might occur in response to injury, these cells do not repair or regenerate the retina. Now, a team from Icahn School of Medicine at Mount Sinai, New York, USA, have shown that they were able to reprogram Müller glia to generate rod photoreceptors, and restore light perception in a mouse model of congenital blindness (1).

Lead investigator, Bo Chen, explained: “This study opens a new pathway for potentially treating blinding diseases by manipulating our own regenerative capability to self-repair” (2). In their study, they reprogrammed Müller glia to generate rod photoreceptors through a two-step process. First, they induced Müller glia proliferation in adult mice through gene transfer of β -catenin. Second, they reprogrammed the proliferating Müller glia cells into rod photoreceptors through gene transfer of the transcription factors *Otx2*, *Crx* and *Nrl*. After confirming that they could generate rod photoreceptors, the team tested whether reprogramming Müller glia in a mouse model of congenital blindness (*Gnat1^{rd17}Gnat^{ppf3}*) could restore visual function. Four weeks after Müller glial

cells were reprogrammed in *Gnat^{rd17}Gnat^{ppf3}* mice, the team were able to show that the mice could respond to light.

Although there is a long way to go between the laboratory bench and the clinic, Chen said that their work could “lead to extraordinary opportunities in the future where we can potentially use the same strategy to reactivate these stem cells in the diseased human eye” (2).



References

1. KYao et al., “Restoration of vision after de novo genesis of rod photoreceptors in mammalian retinas”, *Nature*, [Epub ahead of print] (2018). PMID: 30111842.
2. Mount Sinai Newsroom. “Mount Sinai researchers discover how to restore vision using retinal stem cells”. Available at: <http://bit.ly/MSinai>. Accessed: August 20, 2018.

Bitesize Breakthroughs

Analyzing the tear film layer, screening for neural disease, and a curious contact lens case: a brief selection of the latest ophthalmology news

Eye Spy

- A team at Seoul National University, South Korea, has linked thinning of the retina with Parkinson’s disease (1). In patients with early stage Parkinson’s

disease, the team identified retinal thinning, and found that it correlated with disease severity and may be linked with an increased loss of dopamine-producing brain cells. Looking to the future, the authors hope this study may help neurologists detect Parkinson’s in its earliest stages with a simple eye scan.

Dry Eye Developments

- Using advanced mass spectrometry techniques, a team of Australian researchers have characterized ultra-long-chain fatty acids from human meibum.

The team from Queensland University of Technology in Brisbane are now working with Allergan, who co-founded the research, to incorporate a synthetic long-chain lipid chain into future dry eye treatments (2).

D for Diagnosis


- Researchers at the University of Washington, Seattle, USA, have uncovered potentially promising screening criteria for Alzheimer’s disease. By analyzing a population of 3,855 patients, they identified a significant association between the disease and three common

DISCOVER

LIBERTY[®]



Contact lenses recovered from treated sewage sludge which, according to new research findings, could harm the environment (6).



Credit: Charles Rolsky

eye conditions – AMD, diabetic retinopathy and glaucoma (3).

RP Revelations

- Birch et al. (4) have published findings showing that oral valproic acid was no better than placebo for the treatment of autosomal dominant retinitis pigmentosa (ADRP). In the randomized Phase II multicenter placebo-controlled trial, 37 patients with ADRP were treated for 12 months with 1,000 mg or 500 mg valproic acid; 42 patients were administered placebo. Valproic acid failed to meet its primary endpoint – change in visual field area between baseline and 12 months. The authors noted that one scientific premise for the study was the “concern that patients with RP were taking off-label valproic acid without adequate monitoring.”

Contact Lens Concerns

- In a curious case, a 42-year-old patient presenting with eyelid swelling and ptosis has had a contact lens removed from her eyelid – 28 years after it became embedded there (5). According to the authors, the patient

believed that the lens had been lost at the age of 14 when she was hit in the eye with a shuttlecock during a game of badminton. The authors report it isn't clear why the lens resided in the eyelid asymptotically for 28 years.

- According to findings presented at the American Chemical Society annual meeting, disposable contact lenses are an emerging environmental contaminant (6). As 15–20 percent of contact lens wearers reported flushing their lenses down the toilet or sink, it might be time to check how patients are disposing of their disposables...

References

1. *J Abm et al., Neurology [Epub ahead of print] (2018). PMID: 30111550.*
2. *SE Hancock et al., J Lipid Res., 59, 1510-1518 (2018). PMID: 29907595.*
3. *CS Lee et al., Alzheimers Dement., [Epub ahead of print] (2018). PMID: 30098888.*
4. *DG Birch et al., “Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa”, JAMA Ophthalmol, 136, 849–856 (2018). PMID: 29879277.*
5. *S Patel et al., BMJ Case Rep, (2018). PMID: 30097548.*
6. *American Chemical Society. “The environmental cost of contact lenses”. Available at: <http://bit.ly/ACSLens>. Accessed: August 20, 2018.*

@ ESCRS LUNCHTIME SYMPOSIUM

 Sunday 23rd September 2018 at 1:00 PM – 2:00 PM

 ESCRS – Hall C – Room C2, The Reed Messe, Vienna, Austria

REGISTER NOW!

mediconturevents.com/escrs-2018

In My View

In this opinion section, experts from across the world share a single strongly-held view or key idea.

Submissions are welcome. Articles should be short, focused, personal and passionate, and may deal with any aspect of ophthalmology. They can be up to 600 words in length and written in the first person.

Contact the Editor at edit@theophthalmologist.com

Awakening Sleeping Giants

How and why the laser refractive market is set to grow



By Rod Solar, Director of Practice Development, LiveseySolar, London, UK

What if I said that the size of the laser refractive surgery market could be multiplied fourfold in less than a decade? And that only those with foresight and adaptability will have a chance to grasp this opportunity?

Since the early 2000s, companies have introduced improvements to traditional LASIK, such as wavefront-guided procedures, femtosecond flaps and small incision lenticule extraction (SMILE). Results improved, complication rates declined, and today, LASIK is as safe and effective as ever. Consumers have, however, responded tepidly. Since the financial crisis of the late 2000s, volumes have not grown significantly. The primary target for laser refractive surgeons today is millennials (born 1980–2000). But despite the hopes placed on them to fuel a laser vision correction renaissance, procedure volumes have remained relatively flat since 2009 (1). Why is that? I think a key problem is that equipment manufacturers are optimizing procedures for only one

market segment: people with refractive errors who dislike their glasses and contact lenses enough to opt for laser eye surgery. So far, EyeWorld estimates surgeons have performed 40 million LASIK procedures since 1991 (2). That might sound like a significant number, but considering just how many people worldwide have refractive errors it's an exceedingly small penetration rate.

I think that a significant opportunity is appearing on the refractive horizon: presbyopic LASIK. And I believe that 'Generation X-ers' (born 1965–1979) and 'baby boomers' (born 1946–1964) are the sleeping giants of the refractive surgery market. Here's why:

"I believe that 'Generation X-ers' and 'baby boomers' are the sleeping giants of the refractive surgery market."

1. The market size for presbyopic LASIK is much larger than that of regular LASIK. According to Statista (3), the population of millennials in the USA is estimated to be 72 million, with the population of Generation X-ers estimated at 66 million, and baby boomers at 74 million. But there are together 140

million Generation X and baby boomers – almost double the size. And when you consider that only half of millennials are likely to even need refractive surgery (around 36 million), and compare that with the numbers of people over 50 that have presbyopia (roughly 120 million), it is clear that the presbyopic opportunity is almost four times the size. Of course, as some of these elder Boomers will present with early signs of cataract they will be ideal candidates for refractive lens replacement. With that said, a significant percentage of them will require an enhancement to achieve ‘20-perfect’ vision.

2. People aged over 40, especially emmetropes, are highly motivated to have vision correction treatment for presbyopia. It’s not difficult to understand why so many people who could benefit from laser eye surgery haven’t elected to do it. They’ve adapted to their glasses and contact lenses. But evidence exists in mice that age can limit neural adaptability (4),

which may partly explain why some people over 40 experience difficulty adapting to reading glasses. Though I have yet to find specific evidence supporting this claim, it follows that people tend to exhibit more motivation to address a problem they have trouble adapting to versus a problem they adapted to when they may have been cut ‘were’ more neurologically flexible and plastic (0 to 25 years of age).

3. The presbyopic market has the spending power. Business Insider reports: “Millennials, are spending less on consumer goods because of expensive healthcare and education costs. But baby boomers, are the ‘biggest spenders’ because they have extra cash from decades of saving and investing” (5).

The take home message? Generation X-ers and baby boomers have the size, the motivation and the spending power to potentially quadruple the laser eye surgery market. In my view, presbyopic LASIK is likely to be the most significant opportunity

on the refractive horizon for the next 30 plus years. Growth-minded refractive surgeons should look to new technologies and adapt their marketing strategies for when the sleeping giants awaken.

References

1. Statista. “Number of LASIK surgeries in Europe from 2004 to 2020 (in thousands)”. Available at: <http://bit.ly/EuLASIK>. Accessed: July 31, 2018.
2. Ellen Stodola. “LASIK worldwide”. Available at: <http://bit.ly/LASIKworld>. Accessed: August 15, 2018.
3. Statista. “Resident population in the United States in 2017, by generation (in millions)”. Available at: <http://bit.ly/StatsUSPop>. Accessed: July 31, 2018.
4. M Matamales et al., “Aging-related dysfunction of striatal cholinergic interneurons produces conflict in action selection”, *Neuron*, 90, 362–373 (2016). PMID: 27100198.
5. Ashley Lutz. “Baby Boomers are the sexiest consumers in retail”. Available at: <http://bit.ly/mktBusIn>. Accessed: July 31, 2018.

Financial disclosure: Solar reports that he is a Consultant for Carl Zeiss Meditec.

CYCLO G6™ GLAUCOMA LASER SYSTEM

One laser, three probes for a wide range of glaucoma cases



MicroPulse P3™ Probe

For **MicroPulse mode** and early to advanced glaucoma therapies.



G-Probe™ Device

For **continuous wave mode** and advanced glaucoma therapies.



G-Probe Illuminate™ Device

MicroPulse® mode allows non-incisional, non-destructive, and repeatable treatment. Learn more at iridex.com/cyclog6 and ESCRS booth C501.

Trade-in and limited-time specials available

Pioneer or Buccaneer?

Great minds across the ages have struggled to make their work understood. In the digital age, are we doing enough to push truly pioneering efforts to the forefront?



By Karl Stonecipher, Medical Director of TLC Greensboro, NC, USA

I was lost in a great read the other day: “The Butchering Art” by Lindsey Fitzharris. I asked my staff if anyone had read it – they hadn’t and couldn’t believe a book like that even existed. I explained that it was all about medicine in the early 1800s – before people thought microbes caused disease. Believe it or not, the conversation around infection is still relevant today. Postoperative infection prevention is, and always will be, a number one priority with any type of surgery. Patients don’t want to be hurt as a result of a procedure – not least one you performed.

Which brings me nicely to the point of this article. In 2018, what is the difference between a pioneer and a buccaneer? Technically, a pioneer is defined by Webster as, “a person or group that originates or helps open up a new line of thought or activity” (3). A buccaneer is, “any freebooter preying on Spanish and English ships and settlements, especially in the 17th and 18th century” (4). These guys and girls got out of prison and moved to the Islands. When... they got bored of sipping piña colodas, they decided to take a bold move forward – commander

a boat and rob the Spanish and English oppressing them. That’s what the pirates of the 17th and 18th century are known for, and why the modern definition of a buccaneer is “an unscrupulous adventurer especially in politics or business.”

With that in mind, let’s go back to the 19th century. It was here that one of the most famous doctors of the decade performed an amputation in under three minutes without anesthesia. That’s pretty amazing in itself – until you remember that the technician helping, the medical student watching, and the patient all died. With 300 percent mortality in one procedure, fast isn’t always better. It may be more cost efficient, but does it help the patient?

Fast forward to the early 20th century when a guy called Eddington wanted to prove that another guy called Einstein was a genius. The problem? Everyone was at war. Instead of working on the theory of relativity, scientists were figuring out how to kill soldiers with mustard gas. Eddington decided to go to Africa and prove that Einstein was right, which he did. Immediately, Einstein was hailed a hero back home. In doing so, Eddington proved that the buccaneer was really a pioneer.

In terms of ophthalmology, people like Harold Ridley and Charles Kelman changed the surgical world as we know it, but were hammered by mainstream ophthalmologists of the day. Now, let’s think of the modern ophthalmologist. She has a great idea, but how that idea develops is dependent on where she lives in the world. If it involves embryologic tissue, religion may jump in. If the cost-to-goods are high, private equity jumps in. If she needs to run an investigative review-board sponsored device exemption trial as a surgeon, cost and liability come in to play. Those are just some of the inhibitors to really great ideas today. The old guard hate transition and the new guard embrace it. As the world becomes flatter, we see across the planet in a femtosecond (5). We can think of the ‘new’ world as a big web with thoughts being shared instantly by Googling this or

that, but the exchange of ideas is occurring at a phenomenal rate.

In 2018, we are looking at an explosion of technology to treat dysfunctional lens syndrome – or “I can’t see what I want to without glasses or contact lenses” syndrome. Who is the buccaneer and the pioneer of today? How would Webster define it if he were still alive? The definition could be legal, technical or geographical. We have companies that finally get Food and Drug Administration approval but have ended up bankrupt, while other companies fall out of the running because of a lack of venture capital. Where’s the middle ground between protecting patients from adversity – the buccaneer – and providing patients with sight they want – the pioneer? And how can we make it affordable? That is the million or 100-million-dollar question – because that’s roughly what it costs for a company to participate in an investigator device exemption for an indication for surgery in the US today.

For the most part, Einstein, Ridley, Kelman, and the surgeon today want people to have a better existence. Doctors do what they do to make people better – the money is just a necessary evil. Remember, in the early 19th century, many surgeons weren’t even paid. So what are the hurdles to enlightenment today? How do we create a better world? How do we define the pioneer and the buccaneer? Only time can tell.


References

1. L Fitzharris, “The Butchering Art”, *Scientific American*: October 17, 2017. ISBN: 9780374117290
2. A Isaacson et al, “3D bioprinting of a corneal stroma equivalent. *Experimental Eye Research*”, *Exp Eye Res*, 173, 188-193 (2018). PMID: 29772228
3. <https://www.merriam-webster.com/dictionary/pioneer>
4. <https://www.merriam-webster.com/dictionary/buccaneer>
5. T Friedman, “The World is Flat: A Brief History of the Twenty-First Century”, Farrar, Straus and Giroux: April 5, 2005. ISBN: 1593

It's Time to make a Move

It has never been so simple to adapt new technology into your daily workflow. The truly mobile FEMTO LDV Z8 finally enables you to use next generation femtosecond laser technology for your cataract and refractive surgeries.

www.femtoldv.com



Augenzentrum Zollikofen,
Dr. Baumann, Berne, Switzerland

FEMTO LDV
Z8 Cornea
Cataract

ziemer 
OPHTHALMOLOGY

The FEMTO LDV Z8 is CE marked and FDA cleared for the use in the United States. For other countries, availability may be restricted due to regulatory requirements; please contact Ziemer for details.



A LIFE- CHANGING GIFT

We share the story of one patient, one donor family and one physician to show what it really takes to restore 20/20 vision.

Phoebe Harkin with Crystal Ellis and Christine Sindt

Ophthalmic surgeons perform around 40,000 corneal transplants in the US every year. Here is the story of just one of them. Crystal Ellis was in middle school when she lost sight in her right eye. It took 19 years and the ingenuity of Christine Sindt for her to see properly again.

“Just a regular kid” – the Patient’s Perspective

With Crystal Ellis

It all started in 1999. I was just a regular kid – going through middle school, trying to pass driver’s ed. I woke up one morning with blurry vision in my right eye. I went to the doctor thinking it was an eye infection and they treated it like that for two weeks. When it didn’t go away, they referred me to an ophthalmologist; but they were stumped too. Scarring, which looked like pockets of crystals, suggested a viral infection, but there was no evidence to prove it – and there is still none to this day. Without a diagnosis, there was nothing they could do. And that’s how I lived for the next few years.

A gift that’s impossible to repay

Fast forward to 2005, and my eye was in really bad shape. Everything seemed dark and murky; it was like trying to see through layers of wax paper – there were blobs of color but no definition. Not only that, but the scarring had thinned the corneal tissue. A doctor took one look during a check-up and said, “If you bump your head, your eye could rupture. You need surgery – now.”

It takes a lot to psych yourself up for surgery. I didn’t realize just how much until I woke up and was told that the transplant hadn’t happened. The donated cornea had been cut incorrectly and would have

been rejected by my eye. I was crushed. Luckily for me, it only took two weeks before another became available. So, on June 5, 2005, I got my new cornea.

Part of me thought I would wake up from the transplant and my eye would be like it was before. But it wasn’t at all. My vision had barely improved. Instead of looking through multiple sheets of wax paper, it now felt I was looking through one. I could make out a letter or a number if the writing was big enough, but that was it. I told myself this is how it’s going to be forever. I better get used to it.

About six weeks after the operation, the Iowa Lions Eye Bank asked if I wanted to receive a letter from the donor family. What they sent was beautiful. It was from a mother who had just lost her five-year-old son – my donor. She told me how he had been an outdoorsy, adventurous little boy who loved animals and fire trucks. That’s when it hit me that someone had to die for me to see. This little boy had saved my sight – my life.

I didn’t write back straight away. I just didn’t know what to say... “Thanks, and I’m so sorry your son died,” wasn’t going to cut it. It felt like I could never say enough, so I said nothing. I had already taken an entire semester off college and was just about finding my feet when I discovered I had thyroid cancer. It took another four years before I had a full bill of health.

I was 24 when I finally finished college. I was moving into my first house a year later when I rediscovered and re-read the letter. Why had I never replied? After I stopped crying over what a terrible person I was, I wrote to tell them about everything I had been going through – while admitting it was no excuse for not getting in touch. I told her how I thought about her and her family every day. We wrote each other back and forth and I really got to know her; Misty was a kind, generous woman and mother to a beautiful family.

Fulfilling a dream, reliving a nightmare

I had wanted to go skydiving for a long time, but scarring from the transplant had left me with a thin cornea, and the doctors didn’t know if it could take the pressure of the jump. I got the all-clear just in time for my birthday. I invited Misty and her family to come down as a way of saying thank you for the gift they gave me. They said they couldn’t make it but appreciated the offer.

The big day came and I did the jump. As I landed, I walked past a bunch of people – including my donor family. Apparently, my stepmom had been coordinating with Misty the whole time. It took me a minute but as soon as I realized who they were, I burst into tears. It took seeing Misty in person for me to truly realize that I’d been given a gift I could never repay. Even now, it gives



“That’s when it hit me that someone had to die for me to see. This little boy had saved my sight – my life.”

me goosebumps just thinking about it.

That day was a turning point for me. Misty and her children became my extended family, and now we volunteer together as donor and recipient speakers at the Iowa Lions Eye Bank. It is so rewarding to hear people say, “I was going to write to the people who received my loved one’s organ or tissue, but I didn’t know what to say. Now that I’ve seen how much it means to you, I’m going to reach out to them.” And I know people say the same thing to Misty too. Misty and her family live two hours away, but we get together when we can to share our stories.

Despite accomplishing my dream to skydive and gaining a new extended family, I was still having trouble with my eye. The stitches had started to pop through the surface of the transplant. To remove them, the doctor had to break the knot under the surface, which was uncomfortable. Not only that, my eye didn’t heal correctly: instead of being round, it protruded at the top, and I still couldn’t see much.

A twist of fate

Around the same time, Steven Jacobs – my ophthalmologist since 1999 – was retiring; I didn’t know what I was going to do. Steven, and everyone who worked in his department, were like family to me (I still send them Christmas cards now!). As luck would have it, his replacement was Elizabeth Geiger, who had just done an internship at the University of Iowa, where she’d met a doctor called Christine Sindt. Christine was apparently doing “amazing things” – inventing an entirely custom-made lens that had the potential to correct my vision. Elizabeth got me an appointment right away – and Christine told me I was a great candidate for the lens. The catch? It costs \$4,000 and my health insurance wouldn’t cover it.

AI
Artificial intelligence
Hill-RBF 2.0



LENSTAR 900 AI powered IOL calculation

Artificial intelligence with Hill-RBF

Big data analyzation based on artificial intelligence leading to highly accurate IOL predictions.

Hill-RBF 2.0

The new version is based on a 3x bigger dataset for improved accuracy and confidence. In addition the Hill-RBF was complemented with the well-established Abulafia-Koch algorithm for torical applications.

“It feels strange reflecting on my journey because, for a long time, I didn’t think I’d see properly again and I’d come to terms with that.”


So here it was, the thing I’d been waiting for – a way to see again – and I couldn’t afford it. I almost didn’t want to tell my friends and family about the appointment, because I couldn’t bear to see the disappointment on their faces. But telling them was the best decision I have ever made; they suggested I set up a “YouCaring” webpage to ask for donations. It was actually easier than I thought. I had been sharing my transplant story on Facebook for years, and people had got to know me and my ‘bionic eye.’ I posted a link to the page and within two weeks, I had \$5,000.

I called the clinic that day and told them I had the money. I’m not sure who was more surprised – them or me! From there, the money was split three ways – \$1,000 for the imprint, \$2,500 for the contact, and \$1,500 between office visits, co-pay for a specialty doctor, and tools, solutions and saline sticks to get the contact in and out of my eye. Christine was wonderful through it all – but particularly when it came to the impressions. They were done

Crystal wears a ribbon bearing the face of her donor, five year old Jarren Moser



EyePrintPRO: How it works



with an epoxy mold like the kind you get at the dentist. I remember sitting in the chair watching Christine flick blue goo into a funnel. “What are you going to do with that?”

“We’re going to take a mold of your eye,” she said.

“You’re going to do what?”

She must have seen my face because I was told that it would be totally painless: “I’m going to do it so quick you won’t even know it happened.” And she was right, it didn’t hurt at all.

A second gift

I vividly remember the day I received my lens. It was winter and I was wearing a purple jacket. Up until that day, colors were dull – even with my good eye. Being able to see properly with my new lens made everything so bright. I remember walking out of Christine’s office and seeing a picture of a sunset on the wall. I started bawling. “Look at that picture!” I said. “It’s so orange! Was it always that way?” I couldn’t get over how pretty it was. Even my jacket looked beautiful – how could it be... so purple?

It feels strange reflecting on my journey because for a long time, I didn’t think I’d see properly again and I’d come to terms with that. My eye had healed – no more ‘virus’, no more scar. Getting told there’s a chance I could see was almost worse, because I couldn’t stand the disappointment if it didn’t work. But it did work and now, for the first time in years, I have 20/20 vision. Of course, there have been some teething issues. Trying to tell my brain to use that eye again is hard. After all, I couldn’t see properly for 19 years! You want to simply turn

on a switch, but it doesn’t work that way.

I recently had the honor of representing Team Iowa in the Transplant Games of America. The Games is a multi-sport event for people who have undergone life-changing transplant surgeries. It celebrates the lives of donors and recipients, and raises awareness of the need for organ, eye, bone, and tissue transplants in every US state. When the Iowa Donor Network asked me to take part, I was uncertain at first because I don’t have a competitive bone in my body! But it was Deb Schuett, my contact at the Iowa Lions Eye Bank, who encouraged me to say yes. Deb was the person who put me in touch with my donor family, and we were still very close. With her support, I joined Team Iowa, and we even ended up rooming together at the games! Despite not playing a day in my life, I decided on cornhole and darts. When I told Christine, she couldn’t believe my choice: “Don’t you know darts is a leading cause of eye injuries?!”

The games turned out to be a huge success – not only because I didn’t get hit in the eye, but also because I won gold in darts and two golds in cornhole – one for playing as part of a team, and another as an individual. It must have been beginner’s luck! But the medals were just a small part of what made the games so amazing. I met some phenomenal people, and made new friends that will be part of my life forever. I also got the chance to hear the most beautiful and heartbreaking stories. It was incredibly humbling to consider that many of these people would not be around without organ and tissue donation. But here they were – cheering each other on, celebrating each other’s victories. It was the best experience ever. Life is good.

Seeing Eye to Eye – the Physician’s Perspective

With Christine Sindt

About 20 years ago, I was treating a little girl who fell on a glass. It shattered and a shard went in her eye. She lost the lens and had a large corneal scar that caused a millimeter height difference in her ocular surface. I administered corneal gas permeable lenses for as long as I could, but she became intolerant. I thought there had to be a better way. In eyes that have suffered trauma, like hers, the ocular surface stops being round. If I could just get a lens to lock in to the eye like a Lego piece, I could get this child to 20/20. And that’s really where my journey into “eye printing” all began.

I thought about my patients and decided that I had to develop something that met the unique complexity of their eyes. I wanted the design to work, not just in terms of the eye-to-lens relationship, but also on a human level. Whatever it was, it had to be fast. As physicians, we can make our patients crazy when we don’t have answers. I wanted to be able to say: “This is what’s going to happen next.”

A human(e) approach

This drive to do better for my patients formed the foundation for the EyePrintPRO, an optically clear prosthetic scleral device designed to match the exact contours of each individual eye. We

take an impression of the eye, and then use high-resolution instrumentation to develop a 3D model that can be used to create a custom lens – in as little as two days.


Like all good ideas, it took significant time and effort to get where we are today. And I am very fortunate that I have always had patients with patience! One patient in particular had keratoconus and wasn’t eligible for a transplant, so we kept trying new things. He was with me through more eye impressions than I like to remember until I finally got “the one.” When we discovered he’d got 20/20 vision using his eye print, he cried – and I sat next to him and cried too.

Making a good impression

The impression process was particularly important to me. Previously, molds were made using alginate, which was uncomfortable and painful for the patient. By using polyvinyl siloxanes, we found we could still capture the eye’s precise curvature, without any discomfort. Patients actually call it “cool blue goo.” It doesn’t hurt, it doesn’t need anesthetic, and it doesn’t disrupt anything on the surface of the eye. Not only that, the impressions can be done anywhere. I’ve gone to the bedside of quadriplegic patients, I’ve gone into operating rooms, I’ve gone into the field – and I’ve even done impressions at parties. We can go where people don’t have high-tech devices and high-tech scanners, and offer world-class healthcare in a very affordable way.

Once the impression is taken, it is sent for digitizing. We use the latest 3D scanning technology and numerically controlled

Crystal having her impression taken in Sindt’s office





“Because each lens is custom, it allows us to use really unique optics on the device – and not just in the center as with other lenses.”

machining systems to get an exact match of the individual cornea and sclera. Because each lens is custom, it allows us to use really unique optics on the device – and not just in the center as with other lenses. I can put higher order aberrations on the lens, I can put prism in any direction, I can put a multifocal on the lens, I can do torics – I can even do them all at the same time. And the best part? It all happens so quickly. We use a virtual eyeball to do a theoretical fit to get the best alignment, the best optics, the best comfort – 95 percent of lenses are completed within two attempts. Compare that process with current pre-manufactured designs that use trial and error to find the best fit.

Changing lives

My patients aren't eyeballs in a chair, they are people – and it's always important to remember that. Because what they want to

do – their goals in life – will determine what choices we make together. Oftentimes, there are several different routes we could take, but I can't advise somebody unless I know what's really important to them. And that makes it a very personal journey.

Take Crystal. Her story is unique. By getting to know it, and her, we were able to find a solution. And I'm happy to say her vision is now as fabulous as she is! She has such a positive attitude, despite everything that has happened to her. When I see her, I also see the five-year-old boy who gave his cornea so that Crystal could see. I choke up when I think about it. What I do, I do for people like him and his mom. I do it for all eye donors.

When it comes to my patients, I know I've done a good job when they stop talking to me about their eyes and start showing me pictures: “Do you want to see my kids?” – “Do you want to see where I went on vacation?” It means their eyes aren't their number one concern anymore. I've worked myself out of a job – and that, to me, is a huge success.

Crystal Ellis is a volunteer for the Iowa Lions Eye Bank and the Iowa Donor Network, Iowa, USA.

Christine Sindt is a Director at Contact Lens Service, and a Clinical Professor of Ophthalmology and Visual Sciences at the University of Iowa, Iowa City, USA. Sindt reports that she is Founder of EyePrint Prosthetics and co-creator of the EyePrintPRO. Dr Sindt is the inventor and owner of EyePrint Prosthetics.

OptoProducts

*Sophisticated Technology
Evolved under Alpine Peaks*

Visit us at
ESCRS in Vienna
Booth C605

OPTOTEK
medical
optotek-medical.com



In Practice

*Surgical Procedures
Diagnosis
New Drugs*



30–32

DME, Steroids and Glaucoma
Charles Wykoff addresses concerns of IOP increases when using steroids for management of DME, and highlights the benefits that this treatment approach can have for some patients.

33–35

The Matchmaker
When it comes to cataract surgery training, there is always a learning curve. Paul Ursell presents a system of matching trainees to case complexity – and overviews the benefits it has brought to their clinic.

DME, Steroids and Glaucoma

Addressing concerns about steroid-induced intraocular pressure increases and the risk of glaucoma when managing diabetic macular edema

By Charles C. Wykoff

In my practice, I consider using intravitreal corticosteroids for managing diabetic macular edema (DME) in two categories of patients. First, among patients who respond adequately to anti-VEGF therapy, but the durability of current generation anti-VEGF monotherapies is insufficient for their lifestyle or preference. In this context, utilization of a steroid implant can often achieve a decreased treatment burden. Second, among patients who demonstrate an incomplete response to adequate anti-VEGF dosing.

At a Glance

- *Intravitreal corticosteroids are associated with risks, including IOP elevation which occurs in approximately 30–40 percent of treated patients*
- *Elevated IOP alone does not constitute glaucoma, and when secondary to an intravitreal steroid injection, is usually readily manageable with observation or topical ophthalmic drops in the large majority of cases*
- *For appropriate DME patients, intravitreal corticosteroids can represent a valuable alternative treatment option, with the possibility of a decreased treatment burden.*

There are legitimate reasons to pause before initiating corticosteroid therapy for DME. First, they are well recognized to increase the risk of cataract acceleration. In my view, even a single intravitreal steroid injection permanently changes the trajectory of cataract progression in that eye. Second, they have the potential to increase intraocular pressure (IOP); but there can be misconceptions about the correlation between IOP and glaucoma.

Elevated IOP alone does not constitute glaucoma. This simple distinction is often confused on the podium and in the published literature. While more data is needed related to the scenario of elevated IOP following pharmaceutical interventional, multiple studies have considered the complex relationship of absolute IOP and glaucoma. For example, the Baltimore Eye Survey involving 5,308 individuals (ages 40 years and older who underwent detailed ocular exams including perimetry), reported that even with an IOP of 30 mmHg, the majority of patients (95 percent) did not have glaucoma (1). Additionally, the Ocular Hypertension Treatment Study (OHTS) reported that with an untreated IOP of 24 to 32 mmHg, 9.5 percent of participants developed primary open-angle glaucoma (POAG) after 5 years of follow-up; this rate was reduced in OHTS to 4.4 percent among participants randomized to use of a topical ocular hypotensive medication regimen (2) (Figure 1).

Recognition that elevated IOP is not a surrogate for a diagnosis of glaucoma was highlighted by the removal of IOP as part of the definition of POAG in the American Academy of Ophthalmology (AAO) 2015 Preferred Practice Pattern® Guidelines for POAG (3). The current definition reads in part:

“POAG is defined as a chronic, progressive optic neuropathy in adults in which there is a characteristic acquired

atrophy of the optic nerve and loss of retinal ganglion cells and their axons.”

Elevating the discussion of steroid-induced IOP

While elevated IOP is not synonymous with glaucoma, that does not negate the real clinical concern that steroid treatments can and often do increase IOP in treated patients. Specifically, approximately 30–40 percent of patients treated with intravitreal steroids will experience a clinically relevant elevation of IOP. In consideration of how to manage such an elevated IOP clinically, it may help to consider what we know about its cause and its course in reported prospective clinical trials.

The pathophysiology of IOP elevation following intravitreal steroid treatment is incompletely understood. It is hypothesized that such elevation may be related to increased outflow resistance (4). Specifically, increased IOP may be facilitated by modulation of glucocorticoid receptors within trabecular meshwork cells, theoretically altering the rate of protein synthesis and inhibiting degradation of the extracellular matrix (ECM) (5). However, other studies have reported the opposite (6).

Some of the clinical factors to consider when determining if steroid treatment may be appropriate include historical points such as a personal or immediate family history of POAG, or a history of steroid-induced IOP elevation. Examination findings to consider include higher baseline IOP, high myopia, evidence of glaucomatous nerve damage even in the absence of a definitive diagnosis of glaucoma, and evidence of angle recession. In any of these situations, I am typically more hesitant to consider administering intravitreal steroids.

When treating patients with intravitreal steroids, data from the

prospective MEAD and FAME trials are good sources of information to gauge risk and guide management of IOP elevation. In the MEAD trial, the pooled results from two randomized, sham-controlled, 3-year studies of 347 0.7 mg dexamethasone- and 350 sham-treated patients found that 27.7 percent of patients given dexamethasone had an IOP increase >10 mmHg from baseline; 41.5 percent were prescribed

the collective results of the 36-month FAME trials, which consisted of two randomized, sham-controlled, phase III studies reported that 38.4 percent of 0.2 µg/day fluocinolone acetonide treated patients were prescribed IOP-lowering drops compared to 14.1 percent of control patients. The study also found that while 4.8 percent of 0.2 µg/day fluocinolone acetonide treated patients underwent incisional surgery for elevated IOP, prior ocular steroid treatment correlated strongly with this risk; specifically, no 0.2 µg/day fluocinolone acetonide-treated

patients who received prior ocular steroids required IOP-lowering surgery (9). This finding contributed to the FDA-approved package insert for fluocinolone for DME which requires that patients be “previously treated with a course of corticosteroids” and not have “a clinically significant rise in IOP” (10).


Focusing on management

In my own practice, patients treated with intravitreal corticosteroids are typically monitored every one to two months initially and then at longer intervals, generally not exceeding 3 months, after achieving disease stability. When a patient presents with elevated IOP following intravitreal steroid delivery, how I manage them depends on the degree of IOP elevation and their individual baseline risk profile (11). When possible, since an individual’s IOP can vary, correctly assessing levels and potential treatments are ideally based on several IOP measurements rather than a single assessment. In most cases, I will

“There are legitimate reasons to pause before initiating corticosteroid therapy for DME.”

obtain a retinal nerve fiber layer (RNFL) OCT scan if not already obtained; this allows me to follow their RNFL longitudinally for evidence of thinning.

In the setting of mild IOP elevation, I will often simply observe the patient without intervention and in many cases the IOP will return to baseline as the effect of the steroid diminishes. If IOP rises to above 30 mmHg, regardless of baseline risk status, I often treat with a topical IOP-lowering medication. If IOP has risen more than 10 mmHg but is not above 30 mmHg, I will follow these eyes closely often without treatment. When initiating topical therapy, I typically will use an aqueous suppressant. If intravitreal steroid therapy is continued, I will continue the topical IOP-lowering medication; if intravitreal steroid therapy is discontinued, I will often discontinue the topical IOP-lowering medication once the IOP has normalized. In most cases, steroid-induced elevated IOP can be treated with topical IOP-lowering medications. In cases where alternative or additional treatment is required, laser trabeculoplasty and surgery that could involve either a trabeculectomy or tube shunt are options to consider; I often co-manage these patients with either referring ophthalmologists or referring optometrists comfortable with managing IOP.



IOP-lowering drops compared to 9.1 percent of control patients. The study also found that two patients (0.6 percent) in the 0.7 mg group underwent surgical intervention for elevated IOP, one attributed to steroid-induced IOP elevation and one to neovascularization of the anterior segment (7, 8). Additionally,




Figure 1. OHTS was a randomized trial conducted at 22 clinical centers. A total of 1,636 participants 40 to 80 years of age, with no evidence of glaucomatous damage and an IOP between 24–32 mm Hg in one eye and 21–32 mm Hg in the other eye were randomized to either observation (n=819) or treatment with commercially available topical ocular hypotensive medication (n=817). The goal in the medication group was to reduce the IOP by 20 percent or more and to reach an IOP of 24 mm Hg or less. The primary outcome was the development of primary open-angle glaucoma (POAG) in one or both eyes (2). Log rank P value < .0001, hazard ratio 0.40, 95% confidence interval (0.27, 0.59). Cumulative proportion POAG at 60 months, 9.5 percent in observation group and 4.4 percent in medication group. Adapted from (1, 2, 11).

Summary

With an appreciation of the multiple pathophysiologic pathways involved in DME, corticosteroids can play a role in its management in certain patient populations. Based on current evidence and my experience with patient responses to intravitreal corticosteroids, while IOP elevation is a common clinical reality in treated patients, these elevations are typically readily managed with either observation or topical IOP-lowering medications. Isolated IOP elevation is not equivalent to a diagnosis of glaucoma. The potential benefits of corticosteroids need to be weighed against the risks of cataract acceleration and IOP elevation for each individual patient.

Charles C. Wykoff is Director of Research at Retina Consultants of Houston; Deputy Chair for Ophthalmology at Blanton

Eye Institute; and Associate Professor of Ophthalmology at Weill Cornell Medical College, Houston Methodist Hospital, Houston, Texas, USA.

Wykoff reports the following disclosures: Consultant for Alimera Sciences, Allergan, Bayer, Clearside Biomedical, D.O.R.C. International, Genentech, Novartis, Regeneron, Roche; Speaker for Allergan, Regeneron; and Research Support from Aerpio, Alcon, Allergan, Apellis, Clearside Biomedical, Genentech, Heidelberg, NEI, Novartis, Ophthotech, Regeneron, Roche.

References

1. A Sommer et al, "Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans", *Arch Ophthalmol*, 109, 1090–1095 (1991). PMID: 1867550.
2. MA Kass et al., "The Ocular Hypertension

Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma", *Arch Ophthalmol*, 120, 701–713 (2002). PMID: 12049574.

3. AAO PPP Glaucoma Panel. "Primary open-angle glaucoma PPP - 2015". Available at: <http://bit.ly/2nDB9Eg>. Accessed: August 14, 2018.
4. TF Freddo and H Gong, "Etiology of IOP elevation in primary open angle glaucoma", *Optometric Glaucoma Society E J*, 4 (2009). PMID: 22957318.
5. X Zhang, et al., "Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor- β ", *Invest Ophthalmol Vis Sci*, 46, 4607–4616 (2005). PMID: 16303956.
6. Z Jing-ying Z, et al., "Reversible changes in aqueous outflow facility, hydrodynamics, and morphology following acute intraocular pressure variation in bovine eyes", *Chinese Med J*, 126, 1451–1457 (2013). PMID:23595376.
7. RK Maturi, et al., "OZURDEX® MEAD Study Group: Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study", *Retina*, 23 1143–1152 (2016). PMID: 26871523.
8. DS Boyer, et al., "OZURDEX® MEAD Study Group: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema", *Ophthalmology*, 121, 1904–1914 (2014). PMID: 24907062.
9. RK Parrish, et al., "FAME Study Group: Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials", *Ophthalmic Surg Lasers Imaging Retina*, 47, 426–435 (2016). PMID: 27183546.
10. ILUVIEN prescribing information.
11. BE Prum, et al., "Primary open-angle glaucoma suspect: Preferred Practice Pattern® Guidelines", *Ophthalmology*, 123, P112–P151 (2016). PMID: 26581560.

The Matchmaker

Introducing the easy-to-use system that offers patients lower risks of complications – regardless of surgeon experience

By Paul Ursell

Cataract surgery is very safe – but it could be even safer. A third of all cataract procedures in the UK are performed by trainees; junior trainees have posterior capsule rupture (PCR) rates of 3.2–5.1 percent (1–3), which compares poorly with the overall PCR rate of 1.9 percent. Intuitively, we all know we could improve this situation by protecting less experienced trainees from more difficult cases. But how can we do this in practice? In my clinic, we

At a Glance

- *In the UK, cataract surgery is often performed by trainees – with complication rates two- to three-fold higher than consultants*
- *We have devised a cataract surgery scoring system to stratify patients according to risk, categorize surgeons by experience, and match patients to surgeons accordingly*
- *Data from over 8,000 cases shows that our system removed the association between case complexity and posterior capsule rupture, and almost completely eliminated outcome differences between trainees and consultants*
- *Our system reduces cataract surgery complications, assists practice management and ensures compliance with recent NICE guidelines. We believe the concept is also applicable to other surgical procedures.*



have been matching surgeons to cases on a rational basis for nine years – and our retrospective data analysis (4) shows a significant reduction in complications.

Mix and match

Like much good research, our work has been low tech – but high concept and high impact. In brief, our study builds on a 2009 report (5), which used data from around 56,000 cataract operations to calculate the odds ratio of a surgical complication arising in a given case. Though useful work, it wasn't very user-friendly – it required a complicated program to calculate the complication probability. I wanted to make it easier for

“We haven't eliminated the learning curve in cataract surgery, but we have controlled its impact on patients.”

Examples of cataract surgery and complexity scores (4)

Factors associated with PCR

- Male, assigned score: 1
- Age 80–90 years, assigned score: 2
- Dilated pupil ≤ 4.0 mm, assigned score: 5
- White cataract/ no fundal view, assigned score: 8
- Patient specific score
- Significant hearing impairment, assigned score: 2
- Pachymetry $\geq 600 \mu\text{m}^2$, assigned score: 5
- Permanent VA (other eye) 6/36 or worse, assigned score: 8

Complexity score and trainee recommendations

- Group 1 complexity: total assigned score of 0–1, for trainees with a minimum of 0–50 cases
- Group 5 complexity: total assigned score of ≥ 10 , for trainees with a minimum of 351 cases

clinics to assess the risk of a given case: what we needed, I thought, was a system of classifying both patients and surgeons, and matching them accordingly (see Sidebar).

The first step was to sit down with a group of surgeons, discuss the various case presentations and risk factors, and assign each factor a risk value. We based our approach on the 11 PCR risk factors identified by the cataract national database

(CND); we also incorporated important patient-specific factors (absent in the CND dataset) that suggested an experienced surgeon would be more appropriate than a trainee – for example, patients with corneal edema or only one eye. It took some thought, but eventually we identified 16 risk factors, and assigned them values that fairly represented our own surgical experience.

Next, we needed a sensible way of grouping surgeons according to experience. Bearing in mind that, in the UK, surgeons who have performed 350 or more cataract procedures are deemed competent, we created five skill categories based on procedures performed: 0–50, 50–100, 100–250, 250–350, and 350 or more.

Then, we had to develop a rational way of matching patient scores to surgeon skill and experience. Obviously, a Category 1 surgeon needs to be given the easiest cases, while the most complex cases should be passed to Category 5 individuals – surgeons who've done 350 or more cataract procedures. But where should the risk cut-off points be for each intermediate category? My feeling was that surgeons should reach the stage of 'unconscious competence' – where they can perform effectively without having to think about it – before they move on to the next level. Therefore, we arranged cut-offs with the intent that surgeons don't move up to the trickier levels until they are really competent at the previous level.

Finally, as a test, we checked the scoring system against historical cases where a trainee-operated patient had developed complications. It was so exciting to see that in about 20 percent of cases that had a PCR or other complication during surgery, the trainee had been attempting cases that, according to our scoring system, were beyond their competence. It looked certain that we were onto a winner.

Real-world advantages

The theory was sound – but what about

in practice? As you can imagine, it took a bit of time to introduce it into a multi-disciplinary National Health Service (NHS) department and get everybody on board. But to everyone's credit it was adopted successfully. One reason for that success is the simplicity of the system; the doctor marks a few things on the patient's score card, the nurse adds additional information, such as biometry, and double-checks the information. The result is a total patient score.

We found that our system generated many unforeseen – but welcome – knock-on effects. First, the trainees were much more comfortable knowing their cases were more appropriate to their level. Second, it helped with scheduling: the



trainees and the secretary would organize the list so that there were always cases of an appropriate level for the trainee, and the consultants picked up the rest. Third, the system helps us avoid situations where a case list is over-burdened with difficult cases and leads to surgeries over-running (and when that is unavoidable, the complexity scores justify the time taken, defusing discussions with clinic managers). Fourth, when patients are reluctant for a junior doctor to operate on them, we can reassure them that under our scoring system, trainees only operate within their level of competence. And fifth, it alerts clinicians to complex cases where the patient should, as part of the informed consent obligation, be informed of particular procedure risks.

because the scoring system and outcomes data were stored in different databases. I was very fortunate to be joined by a trainee called Paul Nderitu, who worked on merging the two databases; from six years of operation (January 1, 2011, to December 31, 2016) and 11,468 cases, he extracted complexity data on 8,200 cases. The results of the analysis were better than I'd hoped for: our system had practically eliminated the variation between trainees and consultants in terms of complications and patient outcomes! By rationally allocating cases to appropriate surgeons, we ensured that our patients were subjected to similar chances of complications, and equivalent outcomes, regardless of the surgeon's experience. In other words, the risk of complications is almost the same regardless of whether a trainee or a consultant is operating – simply because we match case difficulty to surgeon competence. It puts me in the happy position of being able to assure patients that they will be allocated a surgeon of a level suitable for their specific needs, and that the outcome won't change – regardless of the individual surgeon.

Good matching

I don't know if others are using our system, but plenty of people have asked me about it over the years. I'd expect increased interest – the NICE guideline on cataract surgery in the UK, which came out earlier this year, recommends that all cataract surgery units use some form of scoring system, and ours is by far the largest and most validated of the available cataract scoring systems. Remember, it was not only derived from validated national cataract data, but also validated with 8,000 of our own cases, which provided strong evidence that our system is effective. If you want to improve outcomes (and comply with NICE guidelines if you are in the UK), you could do far worse than to adopt our system!

The impact has been very positive in our department. And now that people have understood its advantages, it is part of the process.

In fact, we've come to rely on it very heavily; it's considered bad practice when a patient score is missing.

More compatibility, less complication
We've been running this scoring and allocation system in our department for almost a decade now. But analyzing and quantifying its effect was challenging

I believe we've produced something incredibly powerful. Our aim was to minimize complications, optimize outcomes, and maximize patient safety, and I think we have done all of those things. Our system rationally matches patients with surgeons in a way that is good for both. It is ideal for cataract surgery, because the procedure doesn't vary much – but I'm sure the concept could be applied in other types of ophthalmic surgery – or other medical fields, such as orthopedics. To that end, I'd like to explore ways of publicising our work in other surgical disciplines. I'm very proud of what we've done; we haven't eliminated the learning curve in cataract surgery, but we have controlled its impact on patients. And that is a wonderful thing!

Paul Ursell is a consultant ophthalmologist at Epsom & St Helier University NHS Trust, Surrey, UK.

References

1. JM Sparrow et al., "The cataract national data set electronic multi-centre audit of 55 567 operations: case-mix adjusted surgeon's outcomes for posterior capsule rupture", *Eye (Lond)*, 25, 1010–1015 (2011). PMID: 21546922.
2. P Jaycock et al., "The Cataract National Dataset electronic multicentre audit of 55 567 operations: Updating benchmark standards of care in the United Kingdom and internationally", 23, 38–49 (2009). PMID: 18034196.
3. AC Day et al., "The Royal College of Ophthalmologists' National Ophthalmology Database study of cataract surgery: report 1, visual outcomes and complications", *Eye (Lond)*, 29, 552–560 (2015). PMID: 25679413.
4. P Nderitu and P Ursell, "Updated cataract surgery complexity stratification score for trainee ophthalmic surgeons", *J Cataract Refract Surg*, 44, 709–717 (2018). PMID: 30041740.
5. N Narendran, et al., "The Cataract National Dataset electronic multicentre audit of 55,567 operations: Risk stratification for posterior capsule rupture and vitreous loss", *Eye*, 23, 31–37 (2009). PMID: 18327164.

The Measure of All Things

NEW

TrueVision

The perfect link to your
Leica Microscope



Pentacam® AXL Tomographer and Biometer in One Device

In the Pentacam® AXL our tried and true Pentacam® technology has become yet another bit better. Its combination of axis length measurement with anterior segment tomography requires a single measurement process to generate all the data needed for presurgical screening and IOL selection and calculation. Thanks to the TrueVision interface you can now also transmit Pentacam® data directly to your Leica microscope, saving you time, space and money as well as minimizing error sources.



OCULUS at the ESCRS in Vienna, booth B404

Join us at the Lunch Symposium on Saturday, 22nd Sept, 13:00 - 14:00 h

www.pentacam.com

    Follow us!

 OCULUS®

NextGen

*Research advances
Experimental treatments
Drug/device pipelines*



38–40

Engineering Non-Invasive
Refractive Correction

Could the future of refractive surgery be non-invasive? Sinisa Vukelic shares his team's groundbreaking work on corneal cross-linking with low density plasma.

Engineering Non-Invasive Refractive Correction


Could femtosecond laser-induced corneal crosslinking transform standard refractive surgery – and provide a vision correction procedure that is suitable for all?

By Sinisa Vukelic

My laboratory in the Department of Mechanical Engineering at Columbia University (New York, USA) approaches ophthalmology in a very different way from most: in particular, our expertise in biomechanics and laser materials processing

At a Glance

- Normal femtosecond laser surgery employs a highly-focused beam, resulting in a high-density plasma that creates pressure waves, which can disrupt corneal biomechanics and cause post-surgical complications
- By contrast, a loosely-focused femtosecond beam creates a low density plasma (LDP) that does not generate damaging pressure waves
- We have discovered that LDP, by ionizing water and creating oxygen free radicals, creates crosslinks in corneal proteins and thereby alters corneal geometry in a modulatable, predictable way
- Results from animal models suggest that our LDP approach could be the basis of safer, non-invasive, permanent vision correction procedures suitable for virtually all patients.



provides a fresh perspective on the eye. Of course, we've had to learn a lot about collagen and tissue biomechanics – very different from the single crystal and bicrystal mechanics that we've previously worked on – but good things happen when you embrace new concepts and think outside the box. In fact, our open-minded approach helped us make a key discovery: a loosely-focused laser beam can non-invasively modulate corneal geometry and stably alter the eye's refractive power.

Clouds not avalanches

I am a mechanical engineer by training, and have always been fascinated by the plasma physics of ultrafast lasers. In retrospect, this turned out to be the perfect background to kick-start our investigations into the adjustment of corneal biomechanics. Nevertheless, making progress in this field required a great deal of time and effort; for example, once we'd found that a loosely-focused laser beam strengthened the cornea, we had to go back to first principles and do some very basic science to figure out what

was happening. It took years! The end result is a procedure that is rather different from the standard ophthalmological application of lasers – we are using femtosecond lasers not to cut tissue, but to strengthen it by inducing crosslinks.

How does this work? Normally, surgical use of femtosecond lasers relies on 'avalanche ionization,' where multiple photons ionize a substrate molecule; the freed electrons hit electrons associated with other molecules, thereby ionizing other molecules and liberating more electrons, and so on. The cascade effect requires the electron cloud to reach a critical density such that all the incoming photons from the laser pulse are absorbed by electrons, thus creating a dense plasma. Being under pressure, however, the plasma expands and creates damaging shock waves and cavitation bubbles. Hence, normal femtosecond laser operation allows the surgeon to cut a flap in the cornea but also causes unwanted damage, and may lead to post-surgical complications, such as ectasia and corneal weakening.

By contrast, our approach involves



modulating the power and focus of the laser beam such that there are enough photons to create an ionization cloud, but not enough for avalanche ionization and dense plasma formation. The resulting low density plasma (LDP) does not generate shockwaves, and therefore does not damage biological tissue in the same way as a high density plasma. Importantly, however, the LDP ionizes water molecules, thereby generating oxygen free radicals which react with corneal proteins, creating crosslinks that strengthen the cornea in the precise area covered by the laser. The ability to target crosslink induction to very small volumes of corneal tissue allows us to precisely and predictably modulate corneal geometry.

Correction without cutting

Once we had shown that we were creating crosslinks that strengthened the cornea, I knew we'd found something important: a new therapeutic approach that could be tailored to different patients' needs. Our next step was to conduct proof-of-

principle studies in enucleated porcine eyes and in rabbit eyes in vivo (see 'Plasma physics for configuring corneas'). For the in vitro porcine eye studies, we removed the epithelial layer, not because our approach requires it, but because abattoir-sourced eyes often have superficial damage that can interfere with imaging. We didn't need to remove the epithelial layer in the rabbit animal models. Indeed, a big advantage of our method is that it is truly non-invasive.

The results from these animal studies are highly promising. In enucleated porcine eyes, LDP-mediated corneal flattening (as would be used for the treatment of myopia) changed refractive power by about 12 percent (~ 5.11 diopters) during the initial 8 hours. After 24 hours of recovery, refractive power stabilized at ~92 percent (~3.45 diopters) of the initial level. In LDP-mediated corneal steepening (as would be used for the treatment of hyperopia), the refractive power of enucleated porcine eyes increased gradually for 12 hours before stabilizing. In no case was there evidence of laser-induced thermal denaturation or other tissue damage. Additionally, we have very new and exciting – albeit preliminary – observations regarding LDP treatment and keratinocyte populations.

In rabbit eyes in vivo, we observed a relative change in effective refractive power of ~1.94 diopters for treated eyes (the difference between porcine and rabbit eyes in the refractive change achieved is expected, as the two species have very different corneal geometries). Treatment of live rabbits was not associated with the wounds or wound-healing responses seen in refractive surgery. Equally, there was no evidence of thermal damage, such as edema or endothelial cell detachment; microscopy after sacrifice suggested that treated eyes were no different from controls. Some of our treated rabbits have now been followed up for seven months; data suggest that the refractory power change is stable, and confocal imaging indicates that the eyes show no significant structural changes

over this period. And that's exactly what we expected; remember that we are creating covalent bonds, which are difficult to break. Therefore, as long as there is no significant collagen turnover, the refractive power changes we achieve should persist.

We are very pleased with our data so far, but we'd also be delighted to work with anyone who wants to try replicating our results; we all have a duty to make sure that our data are valid. After all, we want to develop a treatment that works every time – 85 or 90 percent success rates are not good enough. Excellent outcomes, every time: that's our goal.

Future focus

Currently, we are moving ahead in two major directions: basic research and clinical development. The former will include extensive parametric studies to ensure that we know exactly what is going on during LDP treatment of the cornea. And however many samples the power analysis tells me I should do, I will always multiply that by five! It upsets the statisticians, but my view is that you only need to mess up once to lose credibility. In addition, we are developing a model that treats crosslinks as external load, and developing equations relevant to this; the aim is to fully understand the cornea's viscoelastic response to the LDP procedure. This knowledge should enable us to precisely tailor LDP treatment to each patient. Treating crosslinks as a load has not been done before, at least not to my knowledge – so there's enough work for two PhD theses! We are also looking at longitudinal studies on the nature of the crosslinks generated by LDP.

With regard to clinical trials, we are working hard on developing suitable device prototypes and procedures. I'd hope to be in human trials by the end of the year, certainly some time in 2019. We are already talking with potential partners about clinical trials in Europe – people have been very enthusiastic whenever we present this work. In particular, we are optimizing

Plasma physics for configuring corneas

Porcine eyes:

- Fresh eyes (~2 hours old; n=60) were mounted in a chamber that permits control of IOP
- Epithelia were removed because of abattoir-associated damage that would interfere with imaging
- A coverslip was applied to press the cornea into a single plane and thereby allow consistent delivery of laser energy over the treated area
- The laser was applied in a boustrophedon pattern; successively deeper 'treatment layers' were achieved by consecutive applications at increasing depth (50 μm increments)
- Treatment of square 5 mm by 5 mm, over the center of the eye,

induced corneal flattening (n=15; matched with 10 controls)

- Treatment of ring-shaped area induced corneal steepening (n=13; matched with 10 controls)
- A separate control study was undertaken to evaluate any effects of experimental set-up itself (n=12)
- After treatment, refractive power was measured hourly over 24 hours
- After 24 hours, corneas were cultured for one week to assess stability of crosslinking

Rabbit eyes:

- Mainly as above, but modified to accommodate live animal (for example, the coverslip arrangement permitted addition of drops to keep eyes moist)
- Epithelium left in place
- Treated area of 5 mm diameter
- Followed up at 24 hours, 7 days, then weekly up to 3 months

the procedure so that it is at least on a par with LASIK with regard to treatment time; everyone would prefer a 5 minute procedure to a 40 minute procedure. We also intend to modify the LDP procedure so that it is applicable to other conditions, including keratoconus, which is the condition we were originally targeting before our ophthalmological colleagues steered us towards refractive surgery. In fact, keratoconus is a great opportunity, given that the current standard of care requires 'epithelium-off' crosslinking. Our 'epi-on' approach would remove many risks, and could represent a significant advance.

We are also looking at applications beyond ophthalmology; for example, applying LDP to articular cartilage in osteoarthritis has given us some fantastic results, and we have now received NIH grants to further pursue this.



Clear benefits

The theoretical advantages are profound. Firstly, being non-invasive, our technique is preferable to standard surgical approaches to vision correction. Furthermore, our approach is gentler than other crosslinking methods: we do not need to peel off the keratocytes, and we don't need to risk damage to keratocytes and epithelial cells by applying UV light, as required in standard crosslinking. Secondly, unlike standard surgical procedures, our method will be applicable to 'difficult' patients; for example, older individuals, patients with thin corneas, people with dry eye syndrome, and those with abnormal corneas. Thus, we hope that many people who are currently ineligible for refractive surgery could be treatable by our method.

I firmly believe that LDP could be the start of a new standard of care in permanent vision correction.



Sinisa Vukelic is a Lecturer in Discipline at Columbia University, New York, NY, USA. His laser research interests lie in laser induced mechanical deformation, single crystal and bicrystal micromechanics and strain gradient plasticity, structural modification of transparent dielectrics and laser imaging and diagnostics.

Reference

1. C Wang, et al., "Femtosecond laser crosslinking of the cornea for non-invasive vision correction", *Nature Photonics*, <https://doi.org/10.1038/s41566-018-0174-8>.

Illustrations by Andy Potts for Vukelic Group and Clarity Vision Technologies





Delivers a 6-image, multi-modal overview in as little as 90 seconds.

Introducing
Monaco

The **ONLY 200°** ultra-widefield
retinal imaging with integrated OCT

Visit us at Euretina/ESCRS, booth #C503
or contact us to put optomap® in your practice at 800 100 4546 or ics@optos.com



A Nikon Company



Building The Retina Company

International CXL 2018 Experts' Meeting

Zurich 2018 Nov 29 - Dec 1



Important dates

Early-bird Registration ends: September 29, 2018

Visa Request Deadline: October 26, 2018

Regular Registration ends: October 31, 2018

All experience levels welcome!

Wetlabs and hands-on workshops on Day 1

www.cxlexpertsmeeting.com

The world's largest Cross-Linking congress

The CXL Experts' Meeting is an independent educational forum dedicated to bringing together corneal cross-linking key opinion leaders with newcomers, industry, and students for a lively full 3-day program.

Thursday, November 29

Wetlabs and Workshops:

Light for Sight wetlab, "CXL for Beginners".

The PACK-CXL workshop: treating infectious and non-infectious melting in both humans and animals.

Oculus Workshop, "Screening for early ectatic disease and keratoconus progression".

SCHWIND eye-tech solutions: "Corneal wavefront-guided treatments and CXL using the AMARIS".

The Light for Sight workshop: Identifying, accessing and managing high-risk patients with keratoconus.

Friday, November 30

Wetlabs and Workshops:

Comprehensive and practical CXL applications.

Saturday, December 1

The latest clinical and basic research findings related to diagnostics: High-speed dynamic Scheimpflug imaging, Brillouin microscopy.

Latest CXL protocols: customized, epi-on, iontophoresis, etc. CXL for ectasia, CXL Plus (combination with refractive surgery). PACK-CXL for infectious keratitis.

New CXL technologies.

Scientific committee

Farhad Hafezi, Theo Seiler, Paolo Vinciguerra, J. Bradley Randleman, Rohit Shetty

Faculty

Renato Ambrósio Jr, Adel Barbara, Michael Belin, Shihao Chen, Efekan Coskunseven, Mouhcine El Bakkali, Frank Famose, Osama Ibrahim, Sabine Kling, Carina Koppen, John Marshall, Cosimo Mazzotta, Jesper Mortensen, David O'Brart, Simon Pot, Frederik Raiskup, Mohamed Shafik, Mazen Sinjab, Emilio Torres, Ricardo Vinciguerra



Powered by





Profession

*Your career
Your business
Your life*



44–48

Overcoming the Mountain of
Global Blindness

Geoff Tabin on why he co-founded
the Himalayan Cataract Project,
and what he hopes to achieve in the
coming years.

Overcoming the Mountain of Global Blindness

The story behind the Himalayan Cataract Project – the NGO eradicating blindness, one country at a time.

By Geoff Tabin

Nepal is the only large, low to moderate income country in the world that has reversed its incidence of blindness, and I'm proud to be part of the reason why. Back in 1995, I co-founded the Himalayan Cataract Project (HCP) with Nepali ophthalmologist Dr. Sanduk Ruit. When we started, there were more than 250,000 people bilaterally blind from cataracts in the Himalayas, with 60,000 more people going blind every year. Nepali surgeons were performing a few thousand cataract surgeries a year, but even fewer were being performed in Tibet, northern India, West Bengal, Sikkim or Bhutan. Today, the number of cataract surgeries performed in Nepal

At a Glance

- *The Himalayan Cataract Project (HCP) was co-founded by Geoff Tabin and Sanduk Ruit in 1995*
- *Aiming to tackle avoidable blindness, the organization began its work in Nepal and has since expanded throughout South Asia and Sub-Saharan Africa*
- *Geoff Tabin tells the story of setting up HCP, and how it all began with a philosophy degree and conquering the world's highest mountain*
- *Tabin also shares his view on how worldwide blindness can be eradicated.*

has risen to more than 350,000 a year. Where once, nearly one in 100 people were blind, the figure now stands at less than three per thousand – the same as the West. And all it took was a five-minute procedure.

If the poorest country in south Asia can eradicate preventable blindness, others can too. By establishing a top-to-bottom system based on compassionate capitalism – where paying patients subsidize surgery to keep costs low – it is possible to provide a high standard of care in even the poorest places. That's what HCP is all about. We empower local people to take control of their healthcare. We train doctors, nurses and technicians at every level, from the primary health care workers to a subspecialty trained ophthalmologists. We know surgeons in developing countries are constrained by lack of equipment, so we try to make sure our partners are as well-equipped as possible.

In the beginning...

HCP came about almost by chance. Back in my early 20s, I was lucky enough to receive a Marshall Scholarship to study philosophy at Oxford University in the UK. At that point, I'd already been accepted to medical school in the US. If it weren't for the scholarship, I would probably be an orthopedic surgeon somewhere doing sports medicine. My time at Oxford gave me time to think about what I wanted to do, and I became interested in the moral paradigm behind healthcare delivery, and the disparity in access to healthcare between countries around the world.

Oxford had a number of endowed funds, including the A C Irvine Travel Fund that provided resources for students to enjoy a strenuous mountaineering holiday abroad. I had always been sporty. I played university tennis and skied from an early age, but I became fanatical about climbing. With the help of the fund, I



HCP Co-Founders Sanduk Ruit and Geoff Tabin with patients at a high volume cataract outreach in Dolakha, Nepal. *Photo by Michael Amendolia.*

Geoff Tabin with a patient who had received sight-restoring cataract surgery in Kalimping, India.

Photo by Ace Kvale.



DMEK

THE INNOVATIVE SYSTEM
FOR TREATING ENDOTHELIAL
CORNEAL DISEASES



- Atraumatic implantation by gentle, touch-free handling of the DMEK graft
- Astigmatism-neutral minimal incision of only 2.4 mm
- Transparent cartridge for perfect control of graft during implantation process

VISIT OUR DMEK LIVE DEMO

at ESCRS booth no. B 102
Sat, Sept 22 + Sun, Sept 23
13:00 - 14:00

www.geuder.com

Geuder[®]
Precision made in Germany



Geoff Tabin with a cataract patient in South Sudan.

Photo by Jordan Campbell.

more or less spent half the year on a paid climbing holiday, scaling big walls in Afghanistan, New Guinea and Africa. The opportunity to climb in Asia and Africa allowed me to witness firsthand the consequences of extreme poverty on health, and the disparity in healthcare systems throughout the world.

My focus was already on global health by the time I matriculated at medical school. As it turned out, I wasn't done with climbing just yet. I was asked to join the first American climbing expedition to Tibet. Together, we would attempt the last unclimbed face on Mount Everest. How could I say no?

I was applying for leave of absence from medical school when I got the phone call that would change everything. After making sure I was Geoff Tabin, the man on the other end said, "You're probably the dumbest person ever accepted into Harvard Medical School." His name was Dr. Michael Wiedman, and he was on the committee reviewing request for leaves of absence. "There's no way that you would ever get a leave of absence to go climbing," he said. "Anybody

with the intelligence to get into this school should know that if you apply to do research, Harvard will give you credits." It turned out he was interested in the effects of high altitude on retinal physiology, specifically high altitude retinal hemorrhaging as a prognosticator of cerebral edema. He said: "Let's forget about your leave of absence and talk about our research project." So we did.

Climbing high

In 1983, while researching under Wiedman, my team and I made the first successful climb of the east side of Everest. It's still the only route done with only local support. It's very technical – more than any other path up the mountain – and it's never been repeated.

After finishing medical school, I had the opportunity to work as a general doctor at one of the hospitals in Nepal that Sir Edmund Hillary, one of my heroes, had established. Many of the problems I faced were public health issues, problems of poverty. I watched children dying of diarrhea and pneumonia and things that would be

so easy to treat in the Western world. Then I saw Dutch ophthalmologist Dr. Jan Kok and his team perform cataract surgery. It was mind-boggling. Before they came, blind people just waited to die. They accepted that you get old, your hair turns white, your eyes turn white, and then you die. In an agrarian economy like Nepal, blindness was a burden for the whole family. Often children would leave school to take care of a blind parent or grandparent. But all it took was a small operation to bring these people back to life. I'd never seen anything in medicine ignite such unbelievable joy. It's hard to express the happiness that a totally blind person feels when they are able to see again.

I knew I could make a difference. I wanted to teach people to perform cataract surgery and immediately sought a residency in ophthalmology. What I didn't know then was that the real genius behind anything that I'd be able to accomplish in the future was also in Nepal – my HCP co-founder Sanduk Ruit. Sanduk grew up in a hill village in Nepal four days' walk from the nearest

FEMTIS® Comfort

road, with no electricity or running water. At eight years old, his father walked him all the way to Darjeeling, India to attend school. He went on to graduate with top honors and won a full scholarship to one of the best medical schools in India.

Upon seeing the level of blindness in his home country, he re-trained as a micro surgeon in the Netherlands with Jan Kok – the same doctor I saw perform cataract surgery in Nepal – and also completed a fellowship in Australia with Dr. Fred Hollows. It was the late 1980s when he returned to Nepal.

At this time, even the least expensive IOLs were cost-prohibitive for the developing world. Sanduk had the genius to team up with his mentor Fred Hollows and his eponymous foundation to raise the funds to start the first low-cost IOL factory in the world, in Kathmandu, instantly reducing the cost of the lenses from \$200 to \$4. In doing so, he transformed the economy of global cataract surgery – a procedure that would cost \$3,000 in the United States now cost \$20 in Nepal.

I heard Fred Hollows lecture in the second year of my residency. I was so impressed by him that I decided to do my corneal fellowship in Australia. Unfortunately, Fred died of cancer before I had chance to start, so I ended up doing my fellowship under Dr. Hugh Taylor, the world authority on river blindness and trachoma. It wasn't until my fellowship that I met Sanduk and everything began to fall into place. He had already set up this amazing system of delivery, taking the best cataract care in India and applying it to Nepal. I was blown away. I finished my fellowship and moved to Nepal to work with Sanduk. That's when HCP was born.

Going above and beyond
During our first cataract outreach together, we restored sight to 224

people in three days. Sanduk did 201 surgeries, while I did 23. The results were incredible. About 80 percent of our patients could see well enough to be able to pass the American driving test one day after surgery. With Sanduk's cataract outreach system, a single doctor in Nepal can provide more than 100 sight-restoring cataract surgeries in a single day.

"The truth is there are very few public health problems we can't overcome"

Unfortunately, people in rural Nepal didn't know they could have their sight restored – they had to be told. And so our mission transformed. Instead of simply teaching doctors, we created an entire system of care. We established primary eye care centers throughout the hills of Nepal, which referred patients to larger regional cataract centers. We expanded upon our now full-service tertiary eye hospital, the Tilganga Institute of Ophthalmology, in Kathmandu. Sanduk also had the brilliant idea of introducing training programs for nurses, ophthalmic assistants, ophthalmic technicians and residents – making us the first hospital in Nepal to develop a full ophthalmology residency program.

On the move
Today, our work is no longer limited to the Himalayas despite our name. We run training sessions throughout the developing world – from Asia to sub-Saharan Africa. We currently have

NEXT FRONTIER IN EDOF-IOL DESIGN:

Turn your Automated Capsulotomies into Great Vision!



programs in Ghana, Ethiopia and Rwanda, and initiatives in Tanzania. One of the biggest problems in Africa is access to care. There are no neuro-ophthalmologists or uveitis specialists in East Africa – or West Africa, for that matter. In Ethiopia, there's one ophthalmologist for every 1,000,000 people – and even that figure is deceptive. Of the 130 ophthalmologists in the country of 105,000,000 people, 30 are either working with NGOs or not doing active surgery, while 60 live in the capital, Addis Ababa, which leaves 40 ophthalmologists to serve the rest of the population – several million people each. You don't have to be a mathematician (or ophthalmologist) to know those numbers aren't good.

To that end, our Ethiopian training program is geared towards high-volume cataract surgery, equipping doctors with the necessary skills and equipment to deal with 1,000 cases a week. As in Nepal, we are still having to reach out to patients. And although this works for now, we are working with local partners and the Ministry of Health to establish permanent healthcare sites to make truly lasting change.

HCP doesn't just visit a place, perform a few surgeries, then leave. We want to make a lasting impact, and we do that by finding partners. We give them the resources they need to do things on their own. We build their skills, provide them with equipment and never show them anything they can't replicate themselves. Talented individuals often go abroad to get a better income, but Sanduk has been incredible at identifying young people who are passionate about staying in their own country. In fact, we're currently in the process of providing fellowships in India, Nepal and America for promising ophthalmologists.

And it's a good thing we are, because

the need for comprehensive eye care continues to grow. In India, the standard of cataract care has become so great that the upper middle class are now paying for surgery before they lose their sight – leaving the destitute blind behind. To understand why that is such a huge problem, think of it on a global scale. If we were to only operate on blind people, we would need to perform about 16,000,000 cataract surgeries. But if we were to operate at the 20/100 level, it's suddenly 60,000,000. And of those extra 44,000,000 people, many have the means to pay. Imagine if we start operating at the level we do in America, 20/60, or England, 6/18 – that number would be eight times higher. Now think of India again. There are many people who have a little trouble seeing their computer or driving at night, and they're willing to pay to make that go away. Paradoxically, as the quality of surgery has improved, less of the surgery is going to the blind.

“We could eliminate avoidable blindness on the planet for the cost of what America spends every month on war.”

When we started out in Nepal, about 80 percent of blindness was due to cataracts. It meant if your dad was blind, you carried him for two days

to see a facility and four out of five times he would come back with his sight. Those are pretty good odds. Good enough that people will come back and actively seek care. But if we played out that same scenario in Africa, things would be different. The continent has more glaucoma, more infectious blindness, and more retinal blindness than Nepal. Even people with cataracts often have glaucoma or corneal scarring from trachoma. Suddenly, the odds of a miracle aren't so high. Half of the people who take two days off from work to carry dad to the doctor won't get cured. Walking another two days home to hungry kids and a father who is still just as blind as he was when you left doesn't incentivize you to proactively visit the clinic. So that's what we're working on right now, a way to transpose and develop a sustainable system of care to the poorest of the poor.

Still climbing

The goal may appear to be unreachable, but the truth is that there are very few public health problems we can't overcome. Blindness can be reversed – it happened in Nepal, it happened in Bhutan, and it can happen elsewhere too. All we need is funding. We could eliminate avoidable blindness on the planet for the cost of what America spends every month on war. Just think about that – two and a half billion dollars could restore sight to every single person who is blind from cataracts. It would take \$100,000,000 to change the arc of blindness in Africa. Our website, which we got by luck, is cureblindness.org – and that's really what we're trying to do. Help us do it. If you are interested in being part of the Himalayan Cataract Project by donating your time or money, email info@cureblindness.org. Together, we can do great things.

MARK YOUR CALENDAR



AOP 2018

INTERNATIONAL - EDITION N°31

14 & 15 DEC

PALAIS BRONGNIART - PARIS

LEARN FROM THE BEST INTERNATIONAL EXPERTS
REGISTER AND DISCOVER THE PROGRAM ONLINE

#33

WWW.AOPCONGRESS.COM

ADVANCED OPHTHALMOLOGIC PRACTICE



Doing Right by Everyone

Sitting Down With... Elizabeth Yeu, Assistant Professor
at Eastern Virginia Medical School and Cornea, Cataract
and Refractive Surgeon with Virginia Eye Consultants, VA, USA

What led you to ophthalmology?

As cliché as it sounds, I've wanted to be in medicine since I was four years old. My mother actually discouraged me from going down the more traditional academic route and encouraged me to explore different interests, but I was drawn to the humanism of medicine.

When did you know you'd made the right choice?

I can honestly say that going into residency was that awakening for me. There was no hands-on OR experience during medical school, so I was anxious about my potential as a microsurgeon. Residency was the "a-ha!" moment when I knew I'd found my calling. It was where so much of my life began. I met my husband during residency, and was able to connect with a profession – and a career – that made me feel alive. It was hugely impactful.

Ophthalmology is such a unique blend of medical and surgical care, it really encompasses the joys of being able to positively impact our patients, and maintain relationships with them at the same time. And, unlike other fields of medicine, morbidity is pretty low. I knew I couldn't desensitize myself from taking care of very sick patients.

What are the highlights of your career so far?

There are two that come to mind. The first occurred very early on in my career – my fellowship training and then faculty position at the Cullen Eye Institute at the Baylor College of Medicine. My four colleagues, including Doug Koch and Steve Pflugfelder, truly covered the breadth of the anterior segment sub-specialty, from complex lens-based surgeries through corneal and external disease management. Not only are they experts within our field, but they are also real

gentlemen. It was a huge deal for me to train under them, but to be colleagues of theirs? That's a sincere highlight. They also taught me that it's all in the details. Between the exposure, the expertise and all that they have contributed to the field, both Doug and Steve are the quintessential clinician scientists.

Do you have any other "heroes?"

Dick Lindstrom to me is in a different realm. I respect him for his continual commitment to ophthalmology, to driving innovation and to putting his money where his mouth is. I recently learned that he was one of the inventors of Opti-Sol, the storage media that we've used for decades with corneal transplantation, which is tremendous in itself. More than that, he donates all of the royalties to different eye banking associations. To have someone like Dick reinvesting funds just to create better technology in the realm of cornea is invaluable. Can you imagine a time when we're able to inject endothelial cells or potentially 4D print ocular tissue? Cornea as a field has been relatively stagnant in therapeutic advancements. We have been doing it the same way with transplantation for decades more or less! And we may have continued, were it not for someone like Dick.

How are you finding motherhood?

It's a "hat" that I'm still growing accustomed to! My kids are five and seven and that's happened in the blink of the eye. Though I know each stage of motherhood is a challenge in itself, I try to sit back and enjoy each moment, tame my impatience and anxieties, while putting every effort into making sure I do a great job. We must strive to be the best people we can be, but we shouldn't beat ourselves up over the failures.

Do you struggle to balance work and motherhood?

Absolutely! The struggle lies in doing right by everybody. It's really exciting to be involved with extracurricular opportunities, whether that's volunteering or working with industry on innovations, but you get to a point when some of these opportunities collide with family commitments. It goes back to not rushing in too quickly and saying "yes!" to everything. I want to do right by those I say yes to!

I gave myself a goal: by the time my children are 10, I need to be around more, because shaping their adolescence is the biggest responsibility I have, aside from my responsibility to my patients.

Outside of ophthalmology, what makes you happy?

My family is the big one! But I also meditate and do yoga. I make sure I take time to refuel. You can't give to others if you don't center yourself spiritually and mentally – something I didn't recognize the importance of 10 years ago.

What advice would you give to your younger self?

Don't rush the process. If there are tough decisions that need to be made – and there will be many, both personal and professional – don't rush them. Step back, enjoy each success and learn from each failure. Ever since I was little, I've rushed, rushed, rushed. I entered school at the age of four, graduated from high school at 17, and entered medical school at 20. It was great to have those opportunities, but I've come to realize there is so much to enjoy in the present because time goes by so quickly.

We should all aspire for greatness, setting slightly unrealistic goals that push us beyond our comfort zones. Whether we're teaching residents or committing to research, we are all helping patients and bettering our field.

THE EFFICACY TO HUNT DOWN IOP NIGHT & DAY



Why risk night-time peaks in IOP^{1,2}
when you can provide more consistent and
sustained 24-hour IOP control vs latanoprost^{3,4}

taflotan[®]
(15 µg/ml tafluprost eye drops)

Saflutan[®]
(15 µg/ml tafluprost eye drops)

NIGHT & DAY IOP REDUCTION¹

Product name: SAFLUTAN[®] tafluprost 15 micrograms/ml eye drops, solution in single-dose container. **Composition:** Eye drops, solution, single-dose container (eye drops). A clear, colourless solution. One ml of eye drops, solution, contains 15 micrograms of tafluprost. One single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost. Please refer to Summary of Product Characteristics (SmPC) for a full list of excipients. **Indication:** Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. As monotherapy in patients who would benefit from preservative free eye drops; insufficiently responsive to beta-blockers. SAFLUTAN[®] is indicated in adults \geq 18 years. **Posology and method of administration:** The recommended dose is one drop of SAFLUTAN[®] in the conjunctival sac of the affected eye(s) once daily in the evening. The dose should not exceed once daily as more frequent administration may lessen the IOP lowering effect. For single use only, one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use. **Use in elderly:** No dosage alteration in elderly patients is necessary. **Paediatric population:** The safety and efficacy of tafluprost in children below age 18 has not yet been established. No data are available. **Use in renal/hepatic impairment:** Tafluprost has not been studied in patients with renal/hepatic impairment and should be used with caution. **Method of administration:** To reduce the risk of darkening of the eyelid skin patients should wipe off any excess solution. As with any eye drops, nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route. If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart. **Contraindications:** Hypersensitivity to tafluprost or to any of the excipients. **Warnings and precautions:** Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation. Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated. The change in iris pigmentation occurs slowly and may not be noticeable for several months. The change in eye colour has predominantly been seen in patients with mixed coloured irises, e.g. blue-brown, grey-brown, yellow-brown and green-brown. There is potential for hair growth to occur in areas where tafluprost comes repeatedly in contact with the skin surface. There is no experience with tafluprost in neovascular, angleclosure, narrow-angle or congenital glaucoma. There is only limited experience with tafluprost in aphakic patients and in pigmentary or pseudoexfoliative glaucoma. Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema or iritis/uveitis. There is no experience in patients with severe asthma. Such patients should therefore be treated with caution. **Interactions with other medicinal products:** No interactions are anticipated in humans, since systemic concentrations of tafluprost are extremely low following ocular dosing. Specific interaction studies with other medicinal products have not been performed with tafluprost. In clinical studies tafluprost was used concomitantly with timolol without evidence of interaction. **Fertility, pregnancy and lactation:** **Women of childbearing potential/contraception:** SAFLUTAN[®] must not be used in women of childbearing age/potential unless adequate contraceptive measures are in place. **Pregnancy:** There are no adequate data from the use of tafluprost in pregnant women. Tafluprost can have harmful pharmacologic effects on pregnancy and/or the fetus/newborn child. SAFLUTAN[®] should not be used during pregnancy unless clearly necessary (where no other treatment options are available). **Breast-Feeding:** It is unknown whether tafluprost or its metabolites are excreted in human milk. Tafluprost should not be used during breast-feeding. **Ability to drive and use machines:** Tafluprost has no influence on the ability to drive and use machines. As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery. **Undesirable effects:** In clinical studies with preserved tafluprost the most frequently reported treatment related adverse event was ocular hyperaemia in approximately 13% of patients. It was mild in most cases and led to an average 0.4% discontinuation. In a 3-month, phase III study comparing the non-preserved formulation of tafluprost with the non-preserved timolol formulation, ocular hyperemia occurred in 4.1% (13/320) of patients treated with tafluprost. The following undesirable effects related to treatment were reported during clinical trials with tafluprost after a maximum follow-up of 24 months: within each frequency grouping, adverse reactions are presented in order of decreasing frequency. **Nervous system disorders:** Common (\geq 1/100 to $<$ 1/10): headache. **Eye disorders:** Common (\geq 1/100 to $<$ 1/10): eye pruritus, eye irritation, eye pain, conjunctival/ocular hyperemia, changes in eyelashes (increased length, thickness and number of lashes), dry eye, eyelash discoloration, foreign body sensation in eyes, erythema of eye lid, superficial punctate keratitis (SPK), photophobia, blurred vision, increased lacrimation, reduced visual acuity and increased iris pigmentation. Uncommon (\geq 1/1000 to $<$ 1/100): blepharal pigmentation, eyelid oedema, asthenopia, conjunctival oedema, eye discharge, blepharitis, anterior chamber cells, ocular discomfort, anterior chamber flare, conjunctival pigmentation, conjunctival follicles, allergic conjunctivitis and abnormal sensation in eye. Frequency not known: iritis/uveitis, deepening of the lid sulcus, macular oedema / cystoid macular oedema. Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas. **Respiratory disorders:** Frequency not known: exacerbation of asthma, dyspnea. **Skin and subcutaneous tissue disorders:** Uncommon (\geq 1/1,000 to $<$ 1/100): hypertrichosis of eyelid. Please also see the SmPC. **Overdose:** Treatment should be symptomatic. **Special precautions for storage:** Store in a refrigerator (2°- 8°C). After opening the foil pouch keep the single-dose containers in the original pouch and do not store above 25°C. Discard opened single-dose containers with any remaining solution immediately after use. **Package quantities:** 30 x 0.3 ml single-dose containers. Low density polyethylene (LDPE) single-dose containers packed in foil pouch. Each single-dose container has a fill volume of 0.3 ml and there are 10 containers in each foil pouch. **MA Holder:** Santen Oy, Niittyhaankatu 20, 33720 Tampere, Finland. **Price:** 30 x 0.3ml single-dose containers £12.20 **MA number:** PL 16058/0017. **Date of Authorisation:** 17/10/2008 **Legal Category:** POM **Date of prescribing information:** December 2017

Prescribing Information No: - NP-SAFLUT-UK-0003

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Santen UK Limited (Email: medinfo@santen.co.uk or telephone: 0345 075 4863).

SAFLUTAN is a registered trademark of Santen Pharmaceuticals Co., Ltd. TAFLUTAN is a registered trademark of Santen Pharmaceuticals Co., Ltd. PP-SAFLUT-EMEA-0025; Date of preparation: May 2018

References: 1. Hughes E. *et al.* J Glaucoma. 2003;12(3):232-6. 2. Wilensky JT. *Curr Opin Ophthalmol* 2004;15:90-2. 3. Konstas AGP *et al.* *Adv Ther* 2017;34(1):221-35. 4. Konstas AGP, *et al.* *Br J Ophthalmol* 2013;97:1510-5.